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ABSTRACT 
AADRA PRASHANT BHATT: Modulation of Host Cell Translation and 
Metabolism by Kaposi’s Sarcoma-associated Herpesvirus 
(Under the direction of Blossom Damania, PhD) 
 
Kaposi sarcoma-associated herpesvirus (KSHV) causes Kaposi sarcoma, 
multicentric Castleman’s disease and primary effusion lymphoma (PEL), an 
aggressive subtype of B cell non-Hodgkin lymphoma (B-NHL). The lack of a 
vaccine, and poorly tolerated standard treatments are the onus for devising 
efficacious therapeutics for KSHV-associated malignancies. Several KSHV 
proteins deregulate cell signaling, creating a favorable environment for viral 
persistence, with cancer being a casualty for the host cell. Thus, understanding 
how KSHV, an obligate intracellular parasite, manipulates host cell processes 
may reveal avenues for therapeutic intervention for these cancers. 
The interplay between KSHV and the host PI3K/AKT/mTOR signaling 
pathway forms the common theme of this dissertation. This signaling pathway 
regulates diverse cellular processes; among them are apoptosis, proliferation 
and metabolism. KSHV encodes several proteins that manipulate this pathway, 
which is highly active in latently infected cells, thus underscoring the importance 
of PI3K/AKT/mTOR signaling for the virus. Therefore, we first examined the 
relative contribution of each arm of this pathway in latently infected PEL cells. We 
found that compared to single inhibitors, dual inhibitors of PI3K/AKT/mTOR 
	   iv 
kinases were significantly more effective at inhibiting PEL proliferation in both in 
vitro and preclinical in vivo models. Dual inhibitors also potently diminished 
autocrine and paracrine proliferative loops, further demonstrating their broad 
efficacy. 
PI3K/AKT/mTOR kinases are essential regulators of cellular anabolic and 
catabolic processes. However, the metabolic sequelae of hyperactive signaling in 
B-NHL were largely unknown. Using metabolomics, we found that two metabolic 
pathways, glycolysis and fatty acid synthesis, were upregulated in latently 
infected PEL cells. Enhanced glycolysis was found to be essential for generating 
intermediates for fatty acid synthesis. The lipid biosynthetic enzyme fatty acid 
synthase is aberrantly expressed in PEL. FASN inhibition induces apoptosis in 
PEL, and further, sensitizes PEL to PI3K/AKT/mTOR inhibitors, highlighting the 
utility of developing FASN as a therapeutic target. 
We discovered that the KSHV viral protein kinase (vPK) activates 
PI3K/AKT/mTOR signaling by phosphorylating the downstream effector 
ribosomal S6 protein, a critical player in protein translation. Furthermore, vPK 
expression imparts resistance to PI3K/AKT/mTOR pathway inhibitors, and 
determining the extent and mechanism of resistance is a future goal of this study.  
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 CHAPTER 1: AKTIVATION OF PI3K/AKT/mTOR SIGNALING PATHWAY BY 
KSHV12 
 
INTRODUCTION 
 Kaposi sarcoma-associated herpesvirus (KSHV; also known as human 
herpesvirus 8) is a human ɣ-herpesvirus that was discovered in Kaposi’s 
sarcoma (KS) biopsies in 1994 (1). Following this seminal discovery, KSHV has 
been found in all forms of KS, including KS associated with AIDS patients, as 
well as HIV-negative and transplant-associated KS. In addition to KS, which is a 
vascular endotheliosarcoma, KSHV is also tightly associated with two 
lymphoproliferative disorders: primary effusion lymphoma (2) and the 
plasmablastic variant of multicentric Castleman’s disease (3), both arising from 
infection of B cells. Owing to the association with these three cancers, KSHV has 
been extensively studied, and the results of these studies have revealed 
fascinating mechanisms by which this oncogenic herpesvirus alters the infected 
cell in order to promote transformation and tumorigenesis. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Aadra P Bhatt and Blossom Damania 2	  This work was originally published as a review in Frontiers in Immunology, doi: 
10/3389/fimmu.2012.00401. 7 January 2013. Copyright © Bhatt and Damania 	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B LYMPHOCYTE DEVELOPMENT  
 B and T cells descend from a common lymphoid progenitor cell, itself 
derived from a hematopoietic stem cell precursor. In humans, B cell development 
occurs in the bone marrow, where the earliest progenitor (or pre-pro) B cell 
expresses germline heavy and light chain immunoglobulin genes (4). As the B 
cell matures, movement along the bone marrow and interaction with stromal cells 
leads to maturation. D-J gene rearrangement occurs in early pro-B cells, and 
continues to V-DJ rearrangement in the late pro-B cell. These gene 
rearrangements create a unique variable domain in the immunoglobulin. Allelic 
exclusion is enforced by the pre-B cell receptor, whereby only one allele 
encoding the rearranged heavy chain is expressed, thereby ensuring that each B 
cell has specificity for a single antigen (4). Many rounds of cell division occur 
during the transition of pro-B cells to the pre-B cell stage, leading to the formation 
of numerous small pre-B cells with a specific rearranged µ heavy-chain gene. 
Pre-B cells undergo light chain gene rearrangement, which is also accompanied 
by allelic exclusion. Since these pre-B cells now produce both heavy- and light-
chain proteins, they are classified as immature B cells, and bear intact IgM 
molecules on their cell surface (4). For a review describing normal B cell 
development, please see (5). 
 In addition to allelic exclusion, isotype exclusion also occurs in immature B 
cells, wherein the immature B cell expresses only one light chain (either λ or κ) 
(4). In humans, because the κ gene rearranges prior to the λ gene, many more 
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mature B cells express the κ light chain rather than λ. The average distribution of 
κ to λ-bearing B cells in humans is approximately 65%:35%, and aberration from 
this ratio is indicative of lymphoproliferative disorders, reflecting dominance of 
one clone (4).  
PATHOPHYSIOLOGY OF KSHV-ASSOCIATED B CELL MALIGNANCIES 
 
Primary	  effusion	  lymphoma: Primary effusion lymphoma mainly afflicts HIV-
infected patients, and occurs in body cavities such as the peritoneal, pleural and 
pericardial cavities (6, 7). Some KSHV-positive lymphomas can also present as 
extranodal solid masses, which may subsequently develop into an effusion. Cells 
have an immunoblastic appearance with a high mitotic index. KSHV-positive 
solid lymphomas represent an extra-cavitary variant of primary effusion 
lymphoma (8). In PEL, every tumor cell expresses between 50-150 copies of the 
KSHV genome. The genome is found as an episome tethered to the host cell 
chromosome by the virus-encoded Latency Associated Nuclear Antigen (LANA) 
protein (9-12).  Some PEL are co-infected with Epstein-Barr virus (EBV), another 
lymphotropic ɣ-herpesvirus (7, 13). 
 Patients with PEL present with lymphomatous effusions within body 
cavities, in the absence of a solid tumor mass (7, 14). Cells contained within the 
effusions are large, with abundant cytoplasm, and display morphological aspects 
common to both large-cell immunoblastic and anaplastic large cell lymphoma (7). 
Analysis of Ig rearrangements suggests that PEL arises from clonal expansion of 
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an infected B cell (6). PEL express syndecan 1/CD138, which is a plasma cell 
surface marker, in addition to CD45 (15). 
 Although most PEL cell lines do not have translocations and mutations as 
associated with c-myc and p53, many PEL possess numerous genetic aberrations 
(16). Sophisticated comparative genome hybridizations (CGH) studies reveal 
extensive copy number aberrations comprising predominantly of gains and 
amplifications. Two genes, SELPLG and CORO1C were found to be the targets of 
amplification at chromosome 12q24.11. SELPLG encodes a membrane-bound 
glycoprotein that binds to P, E and L-selectins, and is important for leukocyte 
recruitment to sites of inflammation (17). CORO1C is a member of the coronin 
gene family that regulate actin-dependent processes such as motility and vesicle 
trafficking, and whose expression is associated with enhanced invasion and 
metastatic capability (18). Deletions of the two fragile site tumor suppressors, 
WWOX and FHIT, were also recently reported in PEL (19).  
Μulticentric Castleman’s disease: Prior to the discovery of KSHV, Castleman’s 
disease, an atypical lymphoproliferative disorder, was divided into the hyaline 
vascular type, and the plasmablastic type. KSHV is associated with the plasma 
cell variant of multicentric Castleman’s disease (MCD), which is multicentric in 
that several lymph nodes and the spleen are involved in disease. In the context of 
HIV infection, MCD is systemic, aggressive, and is associated with high fatality. 
KSHV genomes are detected in almost all HIV+ MCD cases, and ~50% of non-
HIV+ cases of MCD (20, 21). AIDS patients diagnosed with MCD suffer sustained 
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fevers, weight loss, lymphadenopathy and hepatosplenomegaly (22). MCD 
frequently progresses to lymphoma or Kaposi sarcoma.  
  MCD is localized to the marginal zone of lymph nodes and the spleen. The 
germinal centers resemble follicular hyperplasia, and the mantle zone is generally 
intact and surrounded by mature KSHV-infected plasmablasts (23-25). MCD cells 
resemble plasmablast or pre-plasma cells (26). All KSHV-infected plasmablasts 
within the lesion exclusively express the λ light chain of IgM (22), and the 
presence of λ light chains and absence of CD138 on MCD cells further suggest 
they originate from the infection of a less differentiated B cell (27). Lymph nodes 
involved in MCD are characterized by germinal center expansion and vascular 
endothelial proliferation. MCD is characterized by elevated serum IL-6 levels in 
the patient (28). These elevated IL-6 levels, partially augmented by virally 
encoded IL-6 (vIL-6), create an inflammatory microenvironment that significantly 
contributes to the pathophysiology of MCD.  
KSHV ALTERS NORMAL B CELL PROLIFERATION AND DIFFERENTIATION, 
LEADING TO LYMPHOPROLIFERATIVE DISORDERS 
  Both MCD and PEL are associated with infection of a pre-terminally 
differentiated plasma cell. Gene expression arrays indicate that PEL have a 
plasma cell expression profile, and enhanced expression of genes involved in 
inflammation, adhesion and invasion (26), likely contributing to their malignant 
phenotype. MCD is characterized by the polyclonal expansion of KSHV-infected 
plasmablasts that exclusively express the λ light chain. No functional significance 
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exists in whether a plasmablast bears either λ or κ, as the isotype exclusion is 
purely a function of order of light chain gene rearrangement.  
  It was unknown whether KSHV preferentially infected λ light-chain bearing 
B cells due to an inherent, yet unknown survival advantage to the virus/infected 
cell, or whether KSHV infection of a more undifferentiated cell (prior to light chain 
rearrangement) drove the expansion of λ-expressing B cells.  
  Hassman et al attempted to address this question in a recent study in 
which they infected ex vivo suspensions of human tonsillar cells with purified 
KSHV (27). Despite the presence of various cell types, KSHV infection was shown 
to preferentially occur in B cells, as evidenced by LANA+ staining. The tonsillar 
cultures contained both κ- and λ-expressing B cells, however, all LANA+ staining 
was observed within the λ subset. Furthermore, infection with KSHV enhanced 
the proliferation of this IgMλ subset, which was further augmented by treatment 
with IL-6. KSHV-positive cells mirrored phenotypic characteristics of MCD cells, 
such as blasting morphology and increased expression of IgMλ, CD27, Ki67 and 
IL-6R.  
  This study also suggested that rather than naïve B cells, KSHV 
preferentially infects IgM memory B cells, resident within sub-epithelial regions of 
the tonsil and spleen. During plasmablast differentiation, IgM memory B cells 
acquire phenotypic markers such as Ki67+, IgM+ and CD27+, similar to MCD. 
This model is concordant with molecular and seroepidemiological data suggesting 
that the primary mode of KSHV transmission is via saliva (29).  
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Plasmablast differentiation, including that of IgM memory B cells, can 
result from NF-κB activation, a signaling event that occurs during KSHV infection, 
and also during latency. The viral FADD-like IL-1β-converting enzyme 
(FLICE/caspase-8) inhibitory protein (vFLIP) activates NF-κB signaling in latently-
infected cells by associating with the IκB kinase (IKK) complex, and driving 
degradation of IκBα, and thus, NF-κB release into the nucleus. A consequence of 
NF-κB signaling is the promotion of cell survival and proliferation pathways. 
Ballon et al constructed an inducible CD19- or Cɣ1-driven conditional vFLIP 
knock-in mouse, which targeted vFLIP expression to various stages of B cell 
development (30). vFLIP expression in B cells was found to prevent germinal 
center development, Ig class switching, and affinity maturation; vFLIP expression 
resulted in splenomegaly in the mice. Although transgenic mice did not 
recapitulate phenotypes of PEL, B cells mimicked an MCD phenotype, with 
expansion of IgM λ plasmablasts, concordant with the findings of Hassman et al., 
indicating that vFLIP leads to expansion of the IgMλ  subset upon KSHV 
infection. Moreover, impaired GC formation and class switch recombination 
resulting from vFLIP expression suggests that inhibition of the adaptive response 
is a means of escaping immune surveillance.  
Interestingly, 20-month old vFLIP-expressing mice developed B cell-
derived histiocytic/DC sarcoma. This finding is important as it underscores the 
ability of vFLIP to either reprogram or transdifferentiate the infected lymphocytes 
or the bystander cells in a paracrine manner, into other cell types. These findings 
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also reveal insights into the biology of B lymphocytes, and demonstrates their 
inherent plasticity (31). 
 The collective body of research suggests that KSHV viral oncogenesis is 
mediated by expression of both latent and lytic viral gene products. Viral latent 
proteins are expressed in every tumor cell, whereas lytic proteins are expressed 
in a small percentage of tumor cells undergoing reactivation, and are thought to 
promote cell proliferation in an autocrine or paracrine manner.  KSHV can infect 
a wide range of cell types in vitro and in vivo including THP-1 monocytes, 
plasmacytoid dendritic cells, fibroblasts, keratinocytes, B-lymphocytes, 
endothelial and epithelial cells. (27, 32-45). To guarantee successful replication 
within these distinct cell types, KSHV encodes an arsenal of viral proteins that 
are capable of modifying the host cell environment, either directly or indirectly, 
with the outcome being beneficial for the virus. Modulation of host cell pathways 
includes evasion of both immunity as well as apoptosis, induction of cell 
proliferation, and the promotion of cellular metabolism, macromolecular synthesis, 
and protein translation. One way KSHV accomplishes these alterations is by 
targeting the phosphatidylinositol 3’-kinase (PI3K)/AKT/mammalian target of 
rapamycin (PI3K/AKT/mTOR) pathway. Similar to KSHV, many DNA viruses 
encode one or more viral proteins that either activate or inactivate various nodes 
of this pathway (46).  
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KSHV LIFE CYCLE 
 KSHV establishes lifelong latency within the host, punctuated with 
sporadic bouts of reactivation and lytic replication. During latency, the KSHV 
genome exists as a circular, extra-chromosomal viral genome (episome), with 
minimal expression of a subset of latent viral proteins: K12/Kaposin, K13/vflip, 
ORF72/vcyclin, ORF73/LANA, vIL-6 and K1 (47). In contrast, during the lytic 
replication phase, most of the viral genome is expressed and viral assembly, 
egress and dissemination follow viral replication. The lytic switch protein 
Replication and Transcription Activator (RTA) governs KSHV reactivation (48, 
49). Chemicals such as phorbol esters, sodium butyrate, and histone 
deacetylase inhibitors reactivate the virus by activating the RTA promoter (50), 
and thus are useful for studying the viral life cycle. Hormones (norepinephrine 
and epinephrine), cytokines such as interferon-ɣ, oncostatin M and hepatocyte 
growth factor reactivate KSHV, as does the hypoxic microenvironment typical of 
solid tumors and serous cavities, thus stimulating the expression of viral proteins 
that are beneficial to the host cell (51, 52). Terminal differentiation of B cells, 
resulting from expression of X-box binding protein 1 (XBP-1) can also activate 
the RTA promoter, inextricably linking virion production to the host cell life cycle 
(53, 54). Furthermore, stimulation of toll-like receptors (TLRs) 7 and 8 by 
microbes can also reactivate KSHV from latently-infected cells (55); stimulation 
of these pattern recognition receptors generates an anti-viral state, and 
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expressed lytic proteins have many functions which antagonize the host immune 
system.   
 KSHV reactivation from latency significantly alters the physiology of the 
infected cell. Viral replication can reveal viral nuclei acid or peptide motifs that 
can activate host immune surveillance pathways. Viral replication also increases 
the demand for macromolecules such as nucleotides and amino acids to 
synthesize progeny virions. Cellular energy pools are substantially depleted in 
order to fuel the increased biosynthetic rates associated with viral replication. 
The combined effect of enhanced biosynthetic rates and unfulfilled energy 
demands is the activation of cellular stress responses, resulting in cell cycle 
arrest or apoptosis, in an attempt to resolve these deficits. To circumvent 
activation of stress responses, lytic proteins efficiently block cell death pathways, 
and maintain the host cell in a constant state of proliferation. Moreover, many 
lytic and latent proteins co-opt cellular signaling pathways, which sustain 
proliferation, block cell death, and enhance cellular metabolism, in order to 
maintain latent virus or facilitate lytic replication and dissemination of KSHV. One 
such pathway is the pleiotropic PI3K/AKT/mTOR pathway, which governs many 
cellular processes.  
THE PI3K/AKT/mTOR SIGNALING PATHWAY 
 The following brief introduction describes the various effectors of 
PI3K/AKT/mTOR signaling, and relates their activation to distinct physiological 
outcomes for the cell. While no means exhaustive, this description provides a 
primer for subsequent sections, which describe KSHV’s interaction with this 
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pathway. For recent reviews describing up-to-date targets of PI3K/AKT/mTOR 
signaling, their regulation and relevance to malignancies please refer to (56-59). 
 The phosphatidylinositol 3-kinases (PI3K) are lipid kinases that 
phosphorylate the 3’-hydroxyl of the inositol ring of phosphoinositide, a 
component of the interior side of eukaryotic cell membranes (60). 
Phosphoinositides help form membrane cell signaling complexes and are 
essential for intracellular trafficking. PI3K are divided into four classes, IA, IB, II 
and III, all of which have differing substrate specificities and modes of regulation. 
Class IA and IB PI3K catalyze the phosphorylation of phosphatidylinositol-4,5-
bisphosphate (PIP2) at the 3’ carbon on the inositol ring into phosphatidylinositol-
3,4,5-triphosphate (PIP3). PI(3,4,5)P3 production by PI3K allows for pleckstrin 
homology (PH)-domain containing proteins to localize to the plasma membrane 
(60). PIP3 also functions as a cellular second messenger capable of controlling 
cell shape, survival, proliferation, growth, and motility. Class I PI3Ks are 
heterodimeric proteins comprising a regulatory subunit and a catalytic subunit. 
The regulatory subunits are p85α, p85β, p55α, p55ɣ and p50α (60). The catalytic 
subunits are comprised of one of four isoforms: p110α, p110β, p110δ and p110ɣ. 
Most mammalian tissues widely express p110α, β and ɣ catalytic subunits, 
whereas p110δ is restricted to lymphocytes (61). Phosphatase and tensin 
homology (PTEN) is a phosphatase that catalyzes dephosphorylation of the 3’ 
carbon on the inositol of PI(3,4,5)P3 back to PIP2 (62). PTEN is one of the most 
frequently lost tumor suppressors in various cancers. Μutations or deletions in 
PTEN cause hyperactivation of PI3K signaling, leading to increased cell 
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proliferation as well as evasion of apoptosis. AKT is a PH-domain containing 
protein that plays a central role in varied cellular processes such as glucose 
metabolism, evasion of apoptosis, and promotion of cell proliferation, 
transcription and cell migration (63). AKT can also stimulate protein synthesis via 
activation of mTOR (discussed below) (56). Once AKT is localized to the cell 
membrane through its PH-domain, it is phosphorylated on Threonine308 by 
phosphoinositide dependent kinase 1 (PDK1), and Serine473 through the 
mTORc2 complex (64), both of which are activating modifications. AKT has 
several different effectors, which control distinct biological processes, thus, AKT 
activation has pleiotropic effects upon the cell. AKT inhibits cell death by 
phosphorylation-mediated inactivation of pro-apoptotic factors Bad, Caspase-9, 
and the FOXO group of transcription factors (65-68). Phosphorylation of the 
FOXO transcription factors sequesters them within the cytoplasm, thus 
preventing them from transcriptionally activating target pro-apoptotic genes such 
as Fas ligand and Bim.  
 AKT regulates the cell cycle by phosphorylating and inactivating key 
regulators of cell cycle progression. For instance, AKT promotes the 
transcriptional activation of c-Myc and cyclin D1 genes (69), and interacts with 
two regulators of the cell cycle, p27 and p21 (70, 71). Maintaining a quiescent 
state requires high intracellular p27 levels, and PI3K activation was shown to 
reduce the cellular reserves of p27 (72). AKT phosphorylates the p53-induced 
protein p21, a negative regulator of cell cycle progression (70).  The net result of 
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these inhibitory phosphorylation events is the maintenance of cell cycle 
progression and the de-regulation of cellular checkpoint signaling.  
 AKT also activates the non-canonical branch of the NF-κb family of 
transcription factors. NF-κB regulates many aspects of innate and adaptive 
immunity and cell survival. NF-κB is normally sequestered in the cytoplasm by 
inhibitory proteins such as inhibitor of κB (IκBα), which is degraded following 
phosphorylation by the upstream IκB kinase complex (IKK complex), comprised 
of IKKα and IKKβ. IκBα is a direct target of IKKβ, that when degraded, releases 
NF-κB p65 thus activating genes involved in innate immune responses, IKKα 
activates non-canonical NF-κB, leading to formation of p52 which activates 
genes involved in adaptive immunity (73-75), AKT regulates non-canonical NF-
κB p52 processing by increasing the activity of IKKα (76). Studies using 
constitutively active AKT demonstrated elevated p52 transcriptional activity. Non-
canonical NF-κB activity was severely inhibited by using PI3K inhibitors, kinase-
dead AKT or cells lacking AKT isoforms 1 or 2 (76, 77). Thus, AKT modulates 
both cell survival and regulation of adaptive immune responses. De Oliveira and 
colleagues (78) provide an excellent review of the role of NF-κB signaling with 
regard to KSHV infection. 
 The serine/threonine kinase mammalian (or mechanistic) target of 
Rapamycin (mTOR) is a downstream target of PI3K/AKT signaling. In addition to 
being activated by essential signaling pathways such as PI3K and MAPK, mTOR 
is activated by a wide range of cellular stimuli such as growth factors, stress 
signals, and nutrient, energy, and amino acid abundance. mTOR activity is 
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negatively regulated by the tuberous sclerosis complex (TSC), comprised of 
TSC1 and TSC2. TSC2 is an AKT target, and when phosphorylated, inhibits 
Rheb, also a negative regulator of mTOR (63). MTOR exists in two distinct 
multiprotein signaling complexes, mTORc1 and mTORc2, which have differing 
sensitivities to the macrolide rapamycin; mTORc1 is sensitive, whereas mTORc2 
is insensitive. MTORc1 regulates protein translation, cell size regulation, 
intracellular transport, metabolism and lipid biogenesis.  mTORc1 phosphorylates 
S6K1 and 4EBP1, which are two proteins critical for translation of eukaryotic 
capped mRNAs. S6K1 phosphorylates the S6 ribosome, thus stimulating protein 
synthesis. Unphosphorylated 4EBP1 tightly binds and represses the eukaryotic 
initiation factor 4E (eIF4e); hyperphosphorylated 4EBP1 releases eIF4e, thereby 
enabling cap-dependent translation (79). MTOR has a wide plethora of other 
targets for e.g. ULK1 which regulates autophagy (57). Because protein 
translation is central to both cancer growth and viral persistence, mTOR is a very 
important signaling protein. The rapamycin-insensitive mTORc2 complex 
regulates cell survival and cytoskeleton dynamics. MTORc2 activates AKT, 
thereby paradoxically activating AKT/mTOR signaling even upon rapamycin 
treatment, demonstrating a feedback activation loop (80). 
 Solid tumors are characterized by hypoxic microenvironments, therefore, 
de novo angiogenesis as well as remodeling existing blood vessels is essential to 
provide the rapidly growing cells with nutrients and oxygen. The viscosity and 
shear forces of blood against the walls of blood vessels govern the enzymatic 
activity of endothelial cell-expressed NOS (eNOS), and consequently, the 
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continual synthesis and release of nitric oxide (NO). In endothelial cells, AKT is 
activated in a PI3K-dependent manner, both by shear forces and VEGF, which 
collectively activate eNOS (81). NO has pleiotropic functions ranging from 
angiogenesis, remodeling of the vasculature, and the control of blood vessel tone 
(82).  
 The AKT/mTOR axis is a critical regulator of cellular metabolism. 
Activated AKT stimulates glucose uptake by relocalizing the GLUT1 glucose 
transporter, thus bringing glucose into the cell for fueling various cellular 
processes (83). Activation of the mTORc1 complex promotes glycolytic flux, 
upregulates the pentose phosphate pathway, and stimulates de novo lipogenesis, 
all of which contribute to metabolic reprogramming essential for rapidly dividing 
cancer cells (84). 
 As mentioned above, hyperactivation of PI3K/AKT/mTOR signaling is a 
characteristic of many malignancies. Deregulated signaling may result from 
inactivation of negative regulator phosphatases e.g. TSC2 or PTEN, or from 
mutations in catalytic domains of kinases e.g. PIK3CA. Although KSHV-infected 
PEL cells are not known to have activating mutations in any of these three 
kinases, PI3K/AKT/mTOR signaling is highly upregulated in these cells (85, 86). 
As we will discuss further, a variety of viral proteins can activate this signaling 
pathway. 
 Proper PI3K/AKT/mTOR signaling is essential for the differentiation and 
developmental program of normal T and B lymphocytes, as well as other immune 
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cells. PI3K is downstream of numerous cytokine receptors- CD40, Toll-like 
receptors and the BCR itself. The current body of research suggests that PI3K 
signaling regulates the development of bone marrow B cell precursors, as well as 
the differentiation and development of B cell subsets (87-89). Moreover, PI3K 
signaling also governs many aspects of activation and proliferation of mature B 
cells. For an excellent review describing the PI3K pathway with regard to B cell 
development, please see (61).  
KSHV ACTIVATES PI3K SIGNALING DURING DE NOVO INFECTION 
KSHV activates the PI3K signaling pathway during viral infection. The 
widely-expressed proteoglycan heparan sulfate, α3β1 integrins, DC-SIGN and 
xCT are the primary receptors for KSHV, and their differential distribution in 
various cell types contributes to the wide tropism of KSHV (reviewed in (90)). 
KSHV enters target cells by endocytosis. Viral entry activates many cellular 
signaling pathways, which does not require active viral replication, as 
demonstrated by studies using UV-inactivated KSHV (90). Viral ligation of cell-
surface integrins triggers the phosphorylation and activation of focal adhesion 
kinase (FAK) in fibroblasts (91).  FAK further activates downstream signaling 
molecules including Src, Rho GTPases, Diaphanous 2, and PI3K (92-96). In turn, 
these molecules further activate their own downstream effectors such as Ezrin, 
protein kinase C (PKC), MEK, NF-κB, ERK 1/2 and p38 MAPKs, and AKT.  
 Integrin-mediated tyrosine phosphorylation of FAK occurs minutes after 
KSHV infection of fibroblasts (90). Reduced viral genomes and gene expression 
are observed in cells lacking either FAK or Pyk2, a FAK family member, 
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illustrating their essential role in viral infection of target cells. (91, 96). FAK and 
Pyk2 signaling converge onto the Src kinase family, whose downstream effectors 
are PI3K and Rho GTPases. FAK, Src and PI3K are also phosphorylated 
following infection of THP-1 monocytes, as are NF-κB and ERK-1 and 2 (97). 
PI3K activation is crucial for de novo infection due to its activation of various 
GTPases involved in actin cytoskeleton remodeling, endosome formation and 
vesicle trafficking. These intracellular processes allow for viral entry and delivery 
into the nuclear compartment. PI3K and Rho GTPase activation collectively 
induces other Rho GTPase family members, which precipitate the formation of 
subcellular structures such as lamellipodia (through Rac), stress fibers (through 
RhoA) and filopodia (through Cdc42) (91). Further, activation of the PI3K target, 
AKT, leads to the inhibition of pro-apoptotic factors, thus protecting KSHV-
infected cells from cell death.  
 Activation of cellular signaling is imperative for successful viral infection. 
The signaling nodes described above activate the processes of vesicle formation, 
intracellular motility, and evasion of cell death. Furthermore, transcription factors 
activated by these signaling pathways also play a role in activation of the viral 
transcription program, as well as induction of cellular proteins that facilitate viral 
replication. Thus, the collective activation of these intracellular signaling 
pathways creates an environment benefitting the KSHV life cycle. 
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KSHV VIRAL PROTEINS THAT ACTIVATE PI3K/AKT/mTOR SIGNALING 
 Currently, four of the approximately hundred genes and microRNAs 
encoded by KSHV are known to impinge upon the PI3K/AKT/mTOR signaling 
pathway. They are K1, vGPCR, vIL-6 and ORF45. We will discuss the 
mechanisms, extent, context and physiological relevance of each of these 
proteins below. 
K1 
 K1 is the first ORF encoded by KSHV, and is located at the extreme left 
end of the viral genome. K1 is a transmembrane glycoprotein whose expression 
in rodent fibroblasts induces morphological changes and the ability to grow in foci, 
indicating K1’s transformation capacity (98). Further, infection of T lymphocytes 
with a recombinant herpesvirus Saimiri expressing K1 instead of the oncoprotein 
Saimiri transforming protein (STP) conferred IL-2 independent growth, 
suggesting that K1 is also an oncoprotein (98). All KSHV-associated tumors 
express low levels of K1 transcript, and K1 expression is highly upregulated early 
during lytic replication (99-103). K1 transgenic mice leads display constitutively 
active NF-κB and Oct-2 transcription factors, increase in expression of basic 
fibroblast growth factor (bFGF), as well as upregulated expression and activity of 
the Lyn tyrosine kinase (104). A physiological consequence of K1-mediated 
alteration of the cellular transcription program is the development of tumors 
similar to spindle-cell sarcomatoid tumor and malignant plasmablastic lymphoma 
(104). This observation highlights the ability of K1 to exploit the inherent plasticity 
of cell types to induce transdifferentiation. 
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 Various studies describe the extent to which K1 also deregulates normal 
cellular signaling (Figure 1). The regulatory p85 subunit modulates PI3K activity, 
and tyrosine-phosphorylation of p85 results in activation of PI3K (105). K1 
expression leads to increased tyrosine phosphorylation of p85, in addition to 
phosphorylation of Vav and Syk, thus activating signaling networks downstream 
of these kinases, which have pleiotropic effects on the cell (101, 106, 107). 
Further, activation of transcription factors downstream of these kinases, for 
example, NFAT, downstream of Syk signaling, further augments deregulation of 
cellular signaling and promotes cell survival.  
 
  
Figure 1: K1 activates PI3K/AKT/mTOR signaling. 
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In B lymphocytes, ectopic K1 expression was found to activate AKT 
signaling in two simultaneous ways: K1 expression induced AKT phosphorylation 
on Thr308 and Ser473, and also inactivation of the negative regulator PTEN (106). 
K1-mediated AKT activation also induced the cytoplasmic sequestration of the 
FOXO family of transcription factors, and subsequent reduction of Fas ligand 
expression, thus conferring a cell survival advantage to K1-expressing cells (106). 
K1 also stabilizes AKT through interaction with the cellular chaperones heat 
shock protein 90 β (Hsp90β) and the endoplasmic reticulum-associated Hsp40 
(Erdj3/Dnajb11) (108), both of which are important for enhancing the signaling 
function of AKT (109, 110). Chaperone-mediated stabilization of AKT by K1 is 
essential for sustained signaling, as their inhibition induced caspase-3 dependent 
apoptosis in FasL-treated, K1-expressing cells (108). 
 K1’s cytoplasmic tail contains an immunoreceptor tyrosine-based 
activation motif (ITAM) (100, 101). ITAMs are essential for signal transduction in 
immune cells, therefore are found on immunoreceptors, for e.g., CD79 α and β, 
subunits of the B cell receptor complex. Upon ligand binding, the tyrosine 
residues on ITAMs are phosphorylated, which allow for docking of SH2-domain 
containing molecules (Figure 1). Downstream transduction of the extracellular 
signal induces calcium mobilization from the endoplasmic reticulum, and 
activates the lymphocyte. K1 does not require ligand binding to induce signaling, 
thus functions as a constitutively active ITAM (111). The K1 ITAM is closely 
conserved across KSHV strains, indicating the importance of this motif for K1 
function (112, 113). The constitutive activity of the K1 ITAM activates a variety of 
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downstream signaling pathways that not only protect the infected cell, but also 
neighboring cells in a paracrine fashion. Notably, K1 also activates 
PI3K/AKT/mTOR signaling in endothelial cells (102, 114). Components of the K1 
signalosome have been identified, and indicate that the K1 ITAM interacts with a 
diverse set of cellular signaling proteins (115). Overall, K1’s interactions with 
cellular proteins augment global cellular signal transduction, activation of 
transcription facts such as NF-κB and AP-1, and induction of inflammatory 
cytokines (115). 
 Interactions of the K1 N-terminal domain with the BCR complex induce 
BCR sequestration within the endoplasmic reticulum (116). Because normal BCR 
signaling can potentially induce apoptosis, BCR sequestration preempts this 
possibility, thus conferring a long-term survival advantage to the infected cell.  
 K1 expression is upregulated during viral reactivation from latency. Lytic 
replication may induce pro-apoptotic signals resulting from immune detection of 
replicating KSHV. Viral replication places increased demands for energy and 
nutrients on the cell (117) which may be unmet, and possibly activating apoptosis 
resulting from stress signaling. These collective pro-apoptotic signals can be 
subverted by K1 expression (106, 108), thereby supporting productive lytic 
replication and further dissemination of KSHV. Moreover, activating signaling 
downstream of PI3K can also re-start protein translation and metabolic programs, 
halted as a result of apoptosis induction, ensuring that raw materials for 
production of progeny virions are plentiful.  
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KSHV vGPCR 
 KSHV ORF74 encodes a viral G-protein coupled receptor (vGPCR), a 
seven-pass transmembrane protein homologous to the cellular IL-8 chemokine 
receptor (13). vGPCR is a ligand-independent receptor expressed during the lytic 
cycle. Genes expressed during lytic replication are potently transformative, as 
they exert strong survival signals to prolong the life of the host cell, which 
ultimately dies as a result of viral replication and associated cellular stress. 
vGPCR has potent transforming properties; it promotes focus formation in mouse 
NIH3T3 cells, and vGPCR-expressing cells form tumors in nude mice (118). 
Human umbilical vein endothelial cells (HUVECs) are immortalized by vGPCR 
expression, and also protected from apoptosis induced by serum-starvation (119). 
In various mouse models, vGPCR expression leads to formation of vascular 
tumors and KS-like angioproliferative lesions, with cell surface markers and 
circulating cytokine profiles resembling KS (120-122).  
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Figure 2: vGPCR broadly activates PI3K and MAPK pathways. This leads to 
increased production of cytokines and growth factors, with a concurrent increase 
in cell proliferation, and inhibition of apoptotic pathways. Orange circles denote 
phosphorylation. 
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Being a constitutively active receptor protein, vGPCR can function without 
the need of ligand binding (123). However, vGPCR is capable of binding 
members of both CXC and CC chemokine families (124). Some CXC 
chemokines, such as GRO-α and IL-8, enhance vGPCR signaling (125), whereas 
Interferon ɣ-inducible 10-kDa protein (IP-10/CXCL10) and stromal cell-derived 
factor 1 α (SDF-1α) inhibit vGPCR signaling (126). IL-8 is a major mediator of 
inflammation, and recruits neutrophils, basophils and T cells. IL-8 released during 
immune response to lytic KSHV replication may enhance the function of vGPCR 
in lytically infected cells, thereby providing anti-apoptotic signaling to delay the 
death of the infected cell. More puzzling is why SDF-1/CXCL12, a stimulator of 
B-cell progenitor proliferation, inhibits vGPCR activity (126).  However, since 
vGPCR is primarily expressed during the lytic cycle, this might not have a 
consequence for latently infected B cells. 
 KSHV vGPCR activates a plethora of cellular signaling molecules as well 
as transcription factors, by means of which it promotes transformation in 
endothelial, epithelial and fibroblast cells (Figure 2). VGPCR activates pathways 
such as PLC/PKC, Pyk2/Lyn, ERK, p38, and JNK, downstream of which are 
transcription factors that control many growth- and angiogenesis-promoting 
genes. For e.g., HIF-1α activation resulting from vGPCR-dependent p38 and 
MAPK signaling activates the vascular endothelial growth factor (VEGF) 
promoter (127). vGPCR also activates AP-1, NF-AT and NF-κB transcription 
factors, which in turn promote expression of a panoply of pro-inflammatory 
cytokines, growth factors and adhesion molecules (119, 128-130). The vGPCR-
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mediated secretion of such a wide array of factors may enhance proliferation and 
survival in neighboring, uninfected cells in a paracrine manner (Figure 3). Indeed, 
a recent report demonstrates that cytokines secreted by a small number of 
vGPCR+ tumor cells activates signaling pathways in neighboring cells, 
converging on mTOR-dependent VEGF upregulation (131). Inhibiting paracrine 
mTOR activity in non-expressing cells abrogated the tumor promoting activities of 
GPCR-expressing cells in vivo. On the other hand, its expression may directly 
induce transformation of the vGPCR-expressing cell, due to upregulated 
signaling resulting from the same secreted factors. These two methods of 
transformation may act in concert, rather than in isolation, leading to 
transformation of both the infected and bystander cells.  
 PI3K/AKT/mTOR signaling is a common pathway downstream of many 
growth factor and cytokine receptors. In particular, the tissue-restricted ɣ isoform 
of PI3K is crucial for relaying vGPCR signaling downstream to AKT/mTOR, in 
endothelial cells (132). Paracrine secretions resulting from vGPCR expression 
activate PI3K/AKT/mTOR signaling (for e.g. VEGF), and moreover, vGPCR 
directly activates AKT in a PI3K-dependent manner (119).  
 vGPCR expression in the B cell neoplasms PEL and MCD exhibits a 
distinct gene expression profile compared to endothelial cells (133), and is also 
characterized by elevated PI3K/AKT and ERK/p38 MAPK signaling. Ectopic 
vGPCR expression in B cells activates several transcription factors: AP-1, CREB, 
NFAT and NF-κB, thereby promoting cell survival, although the mechanisms of 
activation of these transcription factors differ (134). 
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 As mentioned above, although capable of constitutive activity, vGPCR can 
also signal by coupling with cellular Gαq and Gαi subunits (135), further 
amplifying PI3K/AKT signaling, as both Gαq and Gαi subunits signal through this 
pathway (136). Additionally, vGPCR-mediated activation of AP-1 and CREB, (but 
not NF-κB and NFAT) in B cells was found to be dependent on PI3K/AKT (135). 
VGPCR also activates endogenous Lyn tyrosine kinase in a Gαi- and PI3K-
dependent manner. Pharmacologic and genetic ablation of Src family kinases 
abolished AP-1 and CREB transcriptional activity, confirming that these 
transcription factors are activated by vGPCR through a Gαi-PI3K/AKT-Src 
signaling axis. Further, this study showed that Src inhibitors decreased AKT 
phosphorylation in PEL, indicating that in B cells, Src may be upstream rather 
than downstream of PI3K/AKT signaling, suggestive of a positive feedback loop. 
Importantly, this study revealed that NF-κB and NFAT are not activated in a 
PI3K/AKT dependent manner in B cells (135). Subsequent studies indicated that 
the Ras-related small G protein Rac1 may be required for NF-κB activation via 
vGPCR (137). For an excellent review describing the role of NF-κB signaling in 
the KSHV life cycle please see (78). 
 The previous paragraphs describe the extent to which vGPCR activates 
cellular signaling. The lytically-replicating, vGPCR-expressing cell activates 
transcription factors and signaling entities within the infected cell; induction of 
secreted factors further amplifies signaling in neighboring cells, with the collective 
outcome of enhanced proliferation and sustained survival. 
	   27 
VIRAL INTERLEUKIN-6 (vIL-6) 
 Viral interleukin-6 (vIL-6), encoded by ORF-K2, is a homologue of the 
human IL-6 (hIL-6) cytokine, with 24.8% amino acid sequence similarity and 
49.7% sequence identity (138). Functionally, vIL-6 is a faithful mimic of hIL-6, as 
vIL-6 secreted by KSHV-infected B lymphocytes supports proliferation of B-
lymphocytes and also hIL-6 dependent mouse myeloma cell lines, demonstrating 
its functional similarity (138-140). All latently infected cells express vIL-6, with 
upregulated expression during lytic replication (25, 103, 141, 142). Similar to its 
cellular counterpart, vIL-6 signaling activates the JAK/STAT, MAPK and H7-
sensitive pathways (143). Although v- and hIL-6 have similar sequence and 
function, their receptor usage is substantially different. Cellular IL-6 requires two 
IL-6 receptor subunits: IL-6Rα and gp130. However, vIL-6 is capable of signaling 
via only the gp130 subunit (144). Thus KSHV vIL-6 circumvents the requirement 
for a second receptor, thereby subverting cellular checks against uncontrolled, 
exuberant signaling. 
 vIL-6 is implicated as a linchpin in the pathology of all KSHV-associated 
malignancies, due to its angiogenic properties, as well as potent proliferative and 
survival effects. VIL-6 is detected, in increasing order, in KS, PEL and MCD 
patients (145, 146). However, only a subset of cells express vIL-6 in KS tissue 
(Cannon 1999, Parravicini 2000, Staskus 1999), suggesting that like vGPCR, 
vIL-6 effects are primarily paracrine, activating proliferative signaling pathways in 
bystander cells. Similarly, in MCD, vIL-6 is expressed in lymphoid cells in mantle 
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zones, and hIL-6 was detected in germinal centers (Cannon 1999, Parravicini 
2000, Staskus 1999).  
 Injection of vIL-6-expressing NIH3T3 cells into athymic mice led to tumor 
formation, hematopoiesis, and plasmacytosis, all of which were absent in control 
mice. Tumors derived from vIL-6-expressing cells were highly vascularized, and 
correlated with elevated secreted VEGF (147). A recent report of transgenic mice 
constitutively expressing vIL-6 describes elevated serum vIL-6, increased levels 
of phospho-STAT3 levels in the spleen and lymph nodes, and a manifestation of 
human MCD-like symptoms (148). Importantly, when vIL-6 was constitutively 
expressed in a mouse lacking endogenous hIL-6, no MCD-like symptoms were 
observed. These studies indicate that vIL-6 and hIL-6 cooperate in the 
pathogenesis of MCD.   
 Lymphatic reprogramming resulting from KSHV infection of endothelial 
cells also occurs via engagement of the gp130 receptor (149). Specifically, 
gp130 receptor activation leads to the activation of JAK2/STAT3 and PI3K/AKT 
pathways. Activated AKT promotes the expression of Prox1, a lymphatic 
transcription factor necessary for VEGFR-3 induction, and Prox1 itself is known 
to potentiate the lymphatic reprogramming of endothelial cells upon de novo 
KSHV infection  (150). Furthermore, STAT3 amplifies signaling cascades by 
activating gp130 receptor expression. Podoplanin, another marker of lymphatic 
reprogramming, is also expressed following KSHV activation of gp130. While not 
found to be necessary, vIL-6 is sufficient to induce lymphatic reprogramming in 
endothelial cells infected with KSHV (151). Thus, through gp130, vIL-6 can 
	   29 
enhance lymphangiogenesis and lymphatic reprogramming in both paracrine and 
autocrine manner.  
ORF45 
 ORF45 is an immediate early gene product that plays a crucial role in lytic 
replication. ORF45 expression is induced upon entry into the lytic cycle and 
subsequently increases as the life cycle advances, with expression restricted to 
the cytoplasm. ORF45 is incorporated into the KSHV virion (152), suggesting that 
it may immediately influence the environment of the de novo infected host cell, 
exemplified by the observation that ORF45 acutely inhibits type 1 IFN induction 
upon infection. ORF45 mediates the inhibition of innate immune responses by 
sequestering the cellular transcription factor, interferon regulatory factor-7 (IRF-7), 
to the cytoplasm (153). 
In addition to the modulation of cellular anti-viral responses, ORF45 also 
exerts an effect upon the cellular signaling milieu. Cellular MAPKs are activated 
during KSHV infection (94, 154), and ORF45 interacts with two important MAPK 
substrates RSK1 and RSK2, which are both p90 ribosomal S6 kinase (RSK) 
family members. RSK1 and 2 not only phosphorylate ORF45, but their 
association further augments the kinase activities of these two proteins (155, 
156).  
Another consequence of formation of the RSK/ERK/ORF45 complexes is 
phosphorylation of ribosomal protein S6, and eIF4b, an important member of the 
complex that recruits ribosomes to 5’ capped mRNAs. Phosphorylated eIF4b 
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complexes with eIF4a, eIF4g, 4E-BP1, and 5’ capped mRNAs to recruit the 40S 
ribosome, thereby initiating protein translation. Normally, S6 and eIF4B are 
activated by p70 S6 kinase, itself regulated by upstream mTOR signaling; eIF4B 
is also a target of the p90 S6 kinase, regulated by MAPK signaling. However, 
ORF45 allows for eIF4B phosphorylation in an mTOR- and MAPK-independent 
manner. These observations indicate that protein translation may occur upon 
KSHV infection in an mTOR-independent manner. They also demonstrate the 
existence of unique viral strategies to directly enhance protein translation despite 
a situation within the host cell that may potentially be inhibitory to protein 
translation. 
KSHV-MEDIATED TRANSFORMATION AND THE HALLMARKS OF CANCER 
 The hallmarks of cancer are a conceptual framework to understand the 
multistep progression of cancer (157, 158). The hallmarks of cancer take into 
account that neoplasms, rather than being a singular, isolated entity, are a 
collection of distinct cell types, comprised of tumor cells, tumor-associated 
stroma as well as normal, non-cancerous cells.  These diverse cell types 
cooperate to collectively confer hallmark capabilities, which further enhance the 
development of a tumor microenvironment. Acquisition of one hallmark by a 
normal cell facilitates the development of others, thus increasing the likelihood of 
cellular transformation. The classical hallmarks of cancer are sustained 
proliferation signaling, evasion of growth suppression, replicative immortality, 
induction of angiogenesis, evasion of cell death, and invasion and metastasis. 
Three additional hallmarks have also been recently proposed: deregulation of 
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cellular energetics, tumor-promoting inflammation, and avoidance of immune 
recognition. 
 The endpoint of the productive KSHV life cycle is the production of new 
virions that can subsequently infect new cells, and begin another round of the 
viral life cycle. To successfully replicate and generate progeny virions, KSHV 
must evade immune recognition during latency, and also counter antiviral and 
death-inducing signaling during lytic replication. A plethora of viral proteins 
successfully grant invisibility from immune recognition, and prolong the life of the 
infected cell by altering cellular signaling, as described above.  
Sustained proliferative signaling: Proliferation is a carefully controlled process 
in normal cells. Uncontrolled growth would lead to nutrient scarcity as well as 
overgrowth in the physical niche. Like other cancer cells, KSHV encodes genes 
that activate cellular proliferative pathways both in a paracrine and autocrine 
fashion (Figure 3) (101, 106, 107). This hallmark is particularly evident in KS, as 
not all cells within the lesion are KSHV-positive; expression of viral and cellular 
factors bestows neighboring cells with enhanced proliferative capabilities. 
Sustained proliferation results from growth factor binding to their cognate cell 
surface receptors, and subsequent signaling that further promotes expression of 
the same growth factors and receptors, in a positive feedback loop.  
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Figure 3: Viral proteins enhance cell proliferation by autocrine and paracrine 
mechanisms. Viral and cellular cytokines and growth factors can activate 
signaling pathways within the cell they are secreted from (autocrine), or on 
distant cells that may either be uninfected or latently-infected with KSHV 
(paracrine). RTK= receptor tyrosine kinase. 
 
Evasion of growth suppression and cell death: Powerful growth inhibitory 
programs are intrinsic to the host cell to prevent uncontrolled proliferation. 
Hyperproliferation can trigger cell senescence via activation of checkpoint 
signaling. Alternatively, apoptosis may also result from aberrant oncogene 
activation. Immune cells that detect virally infected cells may also transduce 
apoptotic signals to facilitate viral clearance.  
 KSHV encodes several proteins to protect the infected cell from these 
growth-suppressive and cell death-inducing signals, during latency and the lytic 
cycle. For example, vCyclin, a homolog of cellular Cyclin D forces quiescent 
rodent cells to enter the S-phase to overcome RB-mediated growth arrest 
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induced by CDK inhibitors (159). In the same vein, cells supporting lytic 
replication do not die prematurely despite increased cellular stress, due to the 
presence of viral proteins that inhibit apoptotic signaling. For example, K1-
dependent, AKT-mediated sequestration of FOXO transcription factors and 
inactivation of Bad can protect B cells from apoptosis (106). Similarly, vFLIP 
expression also protects cells from apoptosis by upregulating NF-κB transcription 
and pro-survival factors (160-162). In the context of the whole virus, KSHV-
infected primary HUVEC cells are more resistant to apoptotic stimuli such as 
etoposide, staurosporine and serum-starvation, compared to uninfected cells 
(163). Thus, evasion of both cell death and growth suppression by viral proteins 
expressed during latency and the lytic cycle, contribute to the development of 
KSHV-associated cancer. 
Replicative immortality: Somatic cells within the body divide a finite number of 
times, i.e., they have limited replicative potential. Upon reaching their limit, 
normal cells senesce and cannot proliferate any further. The number of cell 
divisions is governed in part by telomeres, which are stretches of repetitive DNA 
at the ends of chromosomes that shorten after every cell division. However, 
cancer cells can replicate indefinitely owing to activation of one of two pathways:  
activation of human telomerase (hTERT), or the activation of an alternative (ALT) 
pathway, both of which lead to lengthening of telomeres. KSHV LANA has been 
shown to increase the expression of the catalytic subunit of telomerase, hTERT 
by upregulating its promoter, thereby contributing to replicative immortality (164). 
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Additionally, K1 expression in primary HUVECs endows replicative immortality, 
mediated by activation of the ALT pathway (102).  
	  Induction of angiogenesis: All cells, whether normal or otherwise, require a 
reliable blood supply to provide nutrients and oxygen, and to eliminate carbon 
dioxide and metabolic waste products. Tumor cells promote formation of 
vasculature by activating angiogenesis, as well as remodeling of existing 
vasculature and sprouting new vessel growth. Often, tumor-associated vessels 
are erratically branched, aberrantly sized, excessively convoluted and structurally 
unsound, all resulting from hyperactivated induction of angiogenic factors (165, 
166). Vascular endothelial growth factor (VEGF) is a key mediator of 
angiogenesis, and its expression is governed by upstream signaling pathways 
such as PI3K/AKT (167). Other inflammatory cytokines can also drive 
angiogenesis. KSHV vGPCR induces VEGF and VEGF receptor 2 secretion in 
endothelial cells (168). Moreover, K1 expression in epithelial and endothelial 
cells also induces secretion of VEGF and the invasion factor MMP-9 (discussed 
below), as does KSHV infection of endothelial cells (114, 163).  
Invasion and metastasis: Invasion and metastasis are multistep processes that 
begin with local invasion, due to cancer cells exceeding their occupied niche, 
resulting from hyperproliferation. Cancer cells that weakly adhere to neighboring 
cells easily escape and intravasate nearby blood vessels and lymph nodes and 
travel to distal sites through vasculature and lymphatics (169). Some cells 
escape these vessels and enter a new environment, often substantially different 
than the first, forming micro metastases; in the final stage, these grow into larger 
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masses that colonize the new niche, generating metastases (169). Activation of a 
developmental regulatory program termed “epithelial-mesenchymal transition” 
(EMT) bestows onto epithelial cells the ability to invade and metastasize (170, 
171). EMT includes a transcriptional and signaling program, and a similar, 
“endothelial to mesenchymal” (EndMT) transition occurs in the context of KSHV 
infection (172). vFLIP and vGPCR activate the Notch signaling pathway, resulting 
in secretion of the mesenchymal marker membrane type-1 matrix 
metalloprotease (MT1-MMP), granting invasive properties to KSHV-positive cells. 
Significantly, MT1-MMP was found co-localized with LANA in KS biopsies. These 
data suggest that the presence of heterogeneous cell types within KS lesions 
results from viral proteins driving endmt within infected cells, moreover, 
bestowing them invasion capabilities, and the creation of a microenvironment 
that benefits viral dissemination.  
Deregulation of cellular energetics: Recent evidence suggests that the 
reprogramming of cellular energetics and metabolism is an emerging hallmark of 
cancer (reviewed in (158)). Fueling the uncontrolled proliferation and cell division 
of tumor cells requires rewiring of normal cellular energetics. Normal cells, in 
aerobic conditions, utilize glucose to first generate pyruvate and ATP by 
glycolysis, and subsequent mitochondrial oxidative phosphorylation (OXPHOS). 
Anaerobic conditions result in a switch to glycolysis, which is relatively inefficient 
and generates smaller quantities of ATP, which may or may not be accompanied 
by reduced OXPHOS. Otto Warburg observed that cancer cells preferentially 
oxidize glucose by glycolysis even in aerobic conditions, limiting their energy 
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production; this phenomenon is termed the Warburg effect, or aerobic glycolysis 
(173). The Warburg effect is an adaptation of tumors growing in hypoxic 
conditions to generate ATP. KSHV infection of endothelial cells induced the 
Warburg effect, and glycolysis inhibition of latently-infected cells leads to 
apoptosis (174). Moreover, we reported that in KSHV-infected PEL, aerobic 
glycolysis fuels de novo lipid synthesis to generate precursors for daughter cells, 
explaining the significance of upregulating an energetically unfavorable 
biochemical process (175). This study also demonstrated that glycolysis and fatty 
acid synthesis (FAS) occur in a PI3K/AKT-dependent manner, providing a 
mechanism for metabolic reprogramming in PEL. Further, PEL viability was 
found to be susceptible to FAS inhibitors, revealing a new molecular therapeutic 
target.  
Immune evasion: An ever-watchful immune system surveys the body for signs 
of nascent neoplasms, and eliminates such cells. The ability to escape immune 
surveillance is a frequent consequence of genetic instability and aberrant 
signaling in tumors. KSHV-associated tumors are even more able to hide from 
the immune system as viral protein expression can subvert various aspects of 
the innate and adaptive immune response. Viral proteins e.g. KSHV vIRFs, K3, 
K5, etc.  Inhibit immune signaling, protecting the infected cell from host detection. 
For example, the K3 and K5 viral proteins can downregulate both class I and II 
major histocompatibility complexes (MHC), enhancing the immune-evasion 
capabilities of infected cells (176, 177). The KSHV vIRFs also contribute to 
immune evasion (reviewed in (178)). As discussed in previous sections, 
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apoptotic signaling resulting from immune detection is also potently inhibited by 
viral protein expression. 
Tumor-promoting inflammatory microenvironment: Similar to non-viral 
tumors, KSHV-associated lesions are infiltrated by a large number of immune 
cells. KSHV-associated neoplasms are also characterized by elevated local and 
systemic levels of inflammatory cytokines and chemokines, further augmented by 
virally-encoded cytokines such as vIL-6, vMIPs/vCCLs and vOX2. KSHV 
infection also upregulates cyclooxygenase-2 (COX-2), an enzyme that converts 
arachidonic acid into prostaglandins, which are inflammation mediators (179). 
COX-2 is essential for survival of KSHV-infected cells, and viral genome 
maintenance, both of which are susceptible to COX-2 pharmacological inhibitors. 
Creation of an inflammatory environment is functionally significant, since it 
activates signaling in surrounding tissues, and also recruits readily-infectable cell 
types to facilitate viral dissemination.  
EXPLOITING THE PI3K/AKT/mTOR PATHWAY TO TREAT KSHV-
ASSOCIATED MALIGNANCIES 
 Individual KSHV proteins can activate PI3K/AKT/mTOR signaling in B 
cells and endothelial cells, and this pathway is important for both lytic and latent 
phases of the KSHV life cycle. Additionally, both KS and PEL display highly 
activated AKT and mTOR kinases (86, 119, 180). Because aberrant 
PI3K/AKT/mTOR signaling is a characteristic of almost all human cancers, a 
plethora of small molecule inhibitors exist that target various nodes of this 
pathway. These inhibitors include allosteric inhibitors such as rapamycin and 
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FK506, and also ATP-competitive small molecule kinase inhibitors that usually 
target the kinase activity of specific proteins. 
 Rapamycin is a macrolide that binds to FKBP12, a component of the 
mTOR signaling complex (mTORc), and is an allosteric inhibitor (181). 
Rapamycin is commonly used as an oral immunosuppressant for solid organ 
transplant recipients, as it inhibits the production and secretion of IL-2 in T cells, 
thus blocking T cell proliferation. Moreover, rapamycin blocks protein translation. 
Therefore, rapamycin and its derivative compounds called “rapalogs” are 
extensively studied for their therapeutic benefit in a variety of human cancers, 
including those associated with viral infection (182).  
        
  A        B 
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Figure 4: Current NCI-registered clinical trials using inhibitors of the 
PI3K/AKT/mTOR pathway. (A) Stacked bar chart showing the number of trials 
(on the horizontal axis) for different inhibitors (on the vertical axis), grouped by 
mechanism of action. Different colors indicate trial phases. (B) Stacked bar chart 
showing number of trials (on the horizontal axis) for different cancer categories 
(on the vertical axis). Different colors indicate discrete classes of inhibitors. NHL: 
non-Hodgkin lymphoma; HCC: any liver cancer including hepatocellular 
carcinoma; HNC: head and neck cancer; Hem: hematopoietic malignancies 
including multicentric Castleman disease and leukemia; endome: endometrial 
cancer; HD: Hodgkin disease. Figure is adapted from (Dittmer et al, 2012).  
 
Figure 4 graphically summarizes the various PI3K/AKT/mTOR targeted 
therapeutics currently under trial for viral cancers. Rapamycin treatment resolved 
transplant-associated Kaposi sarcoma (183), a seminal finding that has prompted 
many other studies which confirm that rapamycin is an effective anti-cancer drug 
for PEL (86). Specifically, rapamycin is effective at halting the proliferation of PEL 
in cell culture, and, in a xenograft model of PEL, rapamycin inhibits tumor 
formation and induces tumor regression (86). One drawback of rapamycin 
therapy is that it slows tumor growth (tumorstatic), rather than killing tumor cells 
(tumortoxic). Therefore, single agent therapy with rapamycin alone has limited 
benefit in a majority of cancers. 
 A class of AKT inhibitors called alkyllysophospholipids (for e.g. Miltefosine 
and Perifosine) also inhibited PEL cell proliferation both in vitro and in vivo (85). 
Moreover, NVP-BEZ235, a dual inhibitor of both PI3K and mTOR kinases, is a 
potent inhibitor of PEL cell proliferation and tumor formation in xenograft mouse 
models. NVP-BEZ235 treatment induced high levels of apoptosis in PEL (85). 
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Thus, it appears that the PI3K/AKT/mTOR signaling pathway is essential for the 
survival of both PEL and KS tumors. It is of critical importance to evaluate 
whether long-term treatment with small molecule inhibitors breeds resistance to 
pathway-focused inhibitors. Selective pressure resulting from these inhibitors 
could drive expression of viral proteins that may contribute to resistance.  
Therefore in the future, it will be important to investigate whether as yet 
uncharacterized KSHV proteins influence PI3K/AKT/mTOR signaling, both in the 
context of latency and lytic viral replication. 
CONCLUSIONS 
 KSHV is an obligate intracellular parasite, and is a salient example of a 
successful pathogen. Viral manipulation of cellular pathways enhances the 
synthesis and secretion of growth factors and cytokines of both viral and cellular 
origin, which in turn supports angiogenesis and proliferation. These secreted 
growth factors and cytokines can also activate pro-survival, proliferative and 
angiogenic processes in uninfected or latently-infected cells (Figure 3). Thus, by 
manipulating cellular signaling, KSHV viral proteins create an environment 
beneficial for both lytic and latent phases of the viral life cycle. Given the central 
role it plays in cell survival and proliferation, it comes as no surprise that KSHV 
targets the PI3K/AKT/mTOR signaling pathway at multiple nodes, in order to 
induce and sustain a survival and proliferative signal that is advantageous for the 
virus. 
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CHAPTER 2: DUAL INHIBITION OF PI3K AND mTOR INHIBITS AUTOCRINE 
AND PARACRINE PROLIFERATIVE LOOPS IN PI3K/AKT/mTOR-ADDICTED 
LYMPHOMAS3 
 
INTRODUCTION 
The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a critical 
role in cell proliferation and cell survival (Figure 1). PI3K activation stimulates the 
production of phosphatidylinositol 3,4,5 tri-phosphate, which results in activation 
of the kinases, PDK1 and AKT. The lipid phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) protein is a negative regulator of this 
pathway. AKT kinase promotes cell survival by phosphorylating, and thereby 
inactivating, pro-apoptotic factors such as the FOXO transcription factor family, 
GSK-3b, Caspase-9 and Bad(1-4). Phosphorylation of Bad, and the FOXO 
transactivators prevent apoptosis. AKT also phosphorylates p27, a negative 
regulator of the cell cycle, thereby preventing cell cycle arrest. Additionally, AKT 
activation leads to phosphorylation and activation of the mammalian target of 
rapamycin (mTOR), a kinase that stimulates protein synthesis and cell 
proliferation.  	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 Activated mTOR protein can associate with raptor and mlst8/GbL to form 
the mTORc1 complex. The mTORc1 complex induces phosphorylation of p70 S6 
kinase (S6K) leading to phosphorylation and activation of the ribosomal protein, 
S6. MTORc1 also inhibits 4E-BP1, a repressor of eukaryotic initiation factor 
eIF4e. This arm of the mTOR pathway is rapamycin-sensitive. In contrast, the 
mTORc2 complex, which consists of mTOR, mLST8/GβL, mSin1 and Rictor, is 
insensitive to the effects of rapamycin. MTORc2 functions in a feedback loop that 
phosphorylates and activates AKT by phosphorylation at Ser473(5). Hence, 
inhibitors of PI3K/AKT are likely to have broader effects than mTOR inhibitors. 
The nutrient sensor, AMP activated kinase (AMPK), is a negative regulator 
of mTORc1(6).  AMPK controls cellular homeostasis by regulating energy 
production within the cell. AMPK is activated when the cellular AMP/ATP balance 
drops, and this leads to activation of fatty acid oxidation in the liver, lipogenesis, 
stimulation of ketogenesis and inhibition of cholesterol synthesis. The net result 
of modulation of these pathways is the inhibition of mTOR, which results in 
attenuation of protein synthesis until cellular ATP reserves are sufficiently 
replenished. The glitazone class of drugs are known to activate AMPK(7, 8), 
leading us to hypothesize that AMPK activation may be of therapeutic value in 
treating mTOR-addicted lymphomas. Additionally, AMPK activation has 
previously been shown to inhibit some tumor types(8, 9).  
We chose primary effusion lymphoma (PEL) as the target for our 
investigation, because PEL rely heavily on PI3K/AKT/mTOR signaling(10) and 
have a very poor prognosis, with reported median survival times of less than six 
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months(11). PEL is a variant of Non-Hodgkin lymphoma (NHL) and is infected 
with Kaposi sarcoma associated-herpesvirus (KSHV). KSHV is associated with 
multiple cancers in the human population: Kaposi sarcoma (KS), primary effusion 
lymphoma (PEL) and multicentric Castleman disease (MCD). The incidence of 
these cancers is highly increased in the context of HIV infection.  We and others 
have previously shown that individual viral proteins like KSHV K1 activate the 
PI3K/AKT pathway in B cells and endothelial cells(12-16). Another viral protein, 
KSHV vGPCR, can also activate this pathway in endothelial and epithelial 
cells(17-21). KSHV-infected PEL display constitutive activation of the 
PI3K/AKT/mTOR pathway(10). No activating PI3K mutations have been reported 
in PEL, and only two PEL lines display PTEN mutations(22). This suggests that 
in PEL, constitutive activation of PI3K, AKT and mTOR kinases is due to the 
expression of viral proteins.  We previously reported that treatment with 
rapamycin, an mTOR inhibitor, induces cell cycle arrest in PEL and may halt 
clinical progression(10).  Rapamycin inhibits mTORc1, but not mTORc2. 
However, recent literature suggests there is increased mTORc2-mediated 
phosphorylation of AKT, which compensates for mTORc1 inhibition by rapamycin, 
in many cell types and tumors(23). Hence, single agent rapamycin therapy has 
had limited success in the clinic.   
Here, we report the consequences of modulating AKT and AMPK kinases 
individually, as well as simultaneously inhibiting PI3K and mTOR kinases in PEL. 
All the compounds tested are either already FDA-approved or currently in clinical 
trials. We demonstrate that dual inhibition of PI3K and mTOR with a novel, orally 
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bioavailable compound, NVP-BEZ235, is more efficacious than single 
compounds in preventing PEL proliferation and tumor growth in mice. We are the 
first to report that the mechanism of action for NVP-BEZ235 involves the 
inhibition of autocrine and paracrine cytokine and growth factors, which may 
explain the heightened sensitivity of cytokine driven cancers to inhibitors of the 
PI3K/AKT/mTOR pathway.  
 
 
 
Figure 1: Schematic representation of cellular pathways leading to cell survival or 
cell death. The roles PI3K, AKT and AMPK play in signaling pathways important for 
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cell survival or cell death are shown. The influence of rapamycin, rosiglitazone, 
miltefosine, perifosine and NVP-BEZ235 on these pathways is also shown. 
Phosphorylation of proteins is indicated by “+p”. 
  
METHODS 
Cell Culture  
Patient-derived, PEL cell lines (BC-1, BCBL-1, BCLM, BCP-1, VG-1) were 
cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine 
serum, 100 IU/ml Penicillin G, 100 mg/ml Streptomycin (Mediatech), 0.075% 
sodium bicarbonate, 0.05 mm β-mercaptoethanol (Gibco) at 37°C in 5% CO2. 
BC-1 is EBV(+)/KSHV(+), while the other cell lines are KSHV(+). 
Inhibitors 
Perifosine, miltefosine and rosiglitazone were purchased from Cayman 
Chemical. Ciglitazone was purchased from Calbiochem. We are grateful to 
Novartis for providing us with NVP-BEZ235. 
MTS cell proliferation assay 
To observe alterations in growth and proliferation, 2 X 105 PEL cells were 
treated with the therapeutic compounds at the indicated doses or with 
appropriate vehicle as a negative control. Cells were followed for 96 hours, and 
cell viability was determined by trypan blue exclusion performed in quadruplicate. 
Actively metabolic cells were quantified every 24 hours using the Cell Titer 96® 
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Aqueous One Solution Cell Proliferation Assay (Promega) according to the 
manufacturer’s instructions. Absorbance was measured using fluostar OPTIMA 
(BMG Labtech). The absorbance measured at 485 or 490 nm indicates the 
number of metabolically active cells. The IC50 of NVP-BEZ235 was calculated by 
plotting the percent inhibition in proliferation in NVP-BEZ235 -treated cells 
compared to vehicle-treated cells (Y-axis) versus the log of the concentration of 
drug (X-axis). This was done using the statistical analysis program R.  The dose 
of NVP-BEZ235 that reduced cell proliferation to 50% of vehicle-treated cells was 
calculated as the IC50 for NVP-BEZ235. 
 
Western blots 
Cells were treated with various compounds as indicated.  After washing 
harvested cells with ice-cold PBS, cell lysates were prepared in a buffer 
containing 150 mm NaCl, 50 mm Tris-HCl (ph 8), 0.1% NP40, 50 mm NaF, 30 
mm β-glycerophosphate, 1 mm Na3VO4 and 1x Complete Protease Inhibitor 
cocktail (Roche). Equal amounts of proteins were electrophoresed on a 10% 
SDS-PAGE denaturing gel, followed by transfer onto a Hybond™-ECL 
nitrocellulose membrane (GE Healthcare). Membranes were blocked with 5% fat-
free milk for 1 hour at room temperature, followed by overnight incubation at 4°C 
in the indicated primary antibodies directed against either phosphorylated or total 
protein.  The following primary antibodies against phosphorylated proteins were 
used: ampkα (Thr172), AKT (Ser473), AKT (Thr308), FOXO1 (Ser256), GSK3β 
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(Ser9), mTOR (Ser2448), S6K (Thr421/Ser424), S6 ribosomal protein 
(Ser235/236). After washing, the membrane was incubated with anti-rabbit igg 
conjugated to HRP. The results were visualized with the ECL Plus Western 
Blotting Detection System (GE Healthcare) according to the manufacturer's 
instructions. 
Xenograft tumor model 
PEL cells were washed in ice-cold phosphate-buffered saline (PBS, 
Mediatech), counted and diluted in 100 ml of PBS mixed with 100 ml of growth 
factor-depleted Matrigel (BD Biosciences)(10).  1x105 to 7.5x105 BC-1 cells were 
injected subcutaneously into the right flank of NOD.CB17- Prkdcscid/J or CB17- 
Prkdcscid/J mice (Jackson Laboratory, Taconic Inc.). The mice were monitored on 
alternate days for development of palpable tumors (~2mm3), at which point drug 
or vehicle treatments were initiated, and were administered either 
intraperitoneally (miltefosine, perifosine) or by oral gavage (rosiglitazone, NVP-
BEZ235) five days a week. Groups of five to seven mice were used to generate 
PEL tumors and treated with either vehicle or drug cocktail. Each biological 
experiment was repeated multiple times. For rosiglitazone, 0.25% methyl 
cellulose was used as vehicle, and 30 mg/kg or 60 mg/kg rosiglitazone was 
suspended in methyl cellulose.  For perifosine and miltefosine, PBS was used as 
vehicle and 50mg/kg perifosine or miltefosine was dissolved in PBS. For NVP-
BEZ235, the compound was dissolved in a 1:9 v/v mixture of 1-methyl-2-
pyrrolidone (Fluka) and polyethylene glycol 300 (Sigma).  A dose of 40 mg/kg of 
NVP-BEZ235 or equal volume of the vehicle was administered. Tumor diameters 
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were measured using digital calipers, and tumor volume was calculated as 
Volume = a X b X [MAX (a, b)]/2, with a and b being the long and short diameters 
of the tumor. The tumors were excised and fixed in formalin. Statistical analyses 
were performed using linear model fit by maximum likelihood with individual 
animals treated as random effect(24). 
Immunohistochemistry 
Tumors were excised, fixed in 10% neutral buffered Formalin for 5 days, 
paraffin-embedded and then 5 mm sections were prepared on slides. Slides were 
de-paraffinized using Histochoice Clearing Agent (Sigma) and re-hydrated using 
graded ethanol, followed by extensive washing with water.  Endogenous 
peroxidase activity was quenched with 3% H2O2 in 10% methanol solution, and 
antigens were exposed by heating sections for 10 minutes in 1 mm EDTA (ph 
8.0), and cooled to room temperature. Non-specific antigens were blocked using 
a blocking buffer (10% normal horse serum [Vector Labs], 5% BSA [Sigma], and 
0.3% tritonx-100] for one hour at room temperature, followed by an overnight 
incubation at 4°C in blocking buffer containing the indicated antibodies: phospho-
AMPK (Thr172, 1:50), phospho-p70 S6 kinase (Thr421/Ser424, 1:50), phospho-
AKT (Ser473, 1:50), phospho-S6 (Ser235/236, 1:100), all from Cell Signaling 
Technology. Sections incubated in blocking buffer lacking primary antibody were 
used as negative controls. The next day, sections were washed in PBS, 
incubated with biotinylated goat anti-rabbit secondary antibody followed by one-
hour incubation in pre-formed Avidin DH- biotinylated horseradish peroxidase H 
complexes (Vectastain ABC kit, Vector Labs), after which sections were stained 
	   63 
with Vector novared substrate, and washed. Sections were counterstained with 
hematoxylin (Invitrogen), dehydrated using graded alcohols, and mounted using 
Cytoseal XYL (Richard-Allan Scientific). Dried slides were imaged using a LEICA 
DM LA histology microscope and LEICA Firecam software.  
Caspase-3 Assay 
Levels of enzymatically active caspase-3 were quantified using the 
apoalert Caspase Fluorescent assay kit (Clontech), according to the 
manufacturer’s directions. Briefly, 1X106 BC-1 PEL cells were treated with 50 µM 
miltefosine, 50 µM Perifosine, or 20 nm NVP-BEZ235, as well as the respective 
vehicle controls. Cells were harvested and lysed 12 hours later. Equivalent 
micrograms of cell lysate for all samples were incubated with a fluorogenic 
caspase-3 substrate (DEVD-AFC). Cleavage of DEVD by caspase-3 releases 
AFC, the fluorescence of which was measured using a fluostar OPTIMA (BMG 
Labtech) fluorometer, with excitation and emission filter wavelengths set to 400 
and 505 nm respectively. 
Cytokine measurements 
We measured the levels of thirty different cytokines in the growth medium 
supernatants of BC-1 PEL cells using a multi-analyte bead immunoassay 
(Invitrogen Cytokine human 30-plex panel) according to the manufacturer’s 
guidelines. Briefly, diluted (1:2) culture supernatants were incubated with 
internally-dyed polystyrene beads coated with specific antibodies directed 
against one of the cytokines. Proteins in the culture supernatants bind to the 
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antibody-coated beads during a two-hour incubation, after which the beads are 
washed extensively. Biotinylated detector antibodies directed against specific 
proteins are added to the beads, where they bind to proteins derived from culture 
supernatants. After washing, streptavidin-conjugated R-phycoerythrin 
(Streptavidin-RPE) was added to the bead-culture supernatant-derived protein-
detector antibody complexes.  Unbound Streptavidin-RPE was washed off, and 
the bead complexes were analyzed using the Luminex Detection system. 
Cytokine concentrations in culture supernatants were extrapolated based on a 
standard curve generated using manufacturer-supplied standards of each 
cytokine analyte.   
 
RESULTS 
We used several compounds that are either FDA-approved or in clinical 
trials to target multiple arms of the PI3K/AKT/mTOR pathway (Figure 1). The 
glitazone class of drugs eg. Ciglitazone and rosiglitazone have been shown to 
activate AMPK(7, 8). Activated AMPK1 directly phosphorylates and activates 
TSC2(25, 26) leading to inactivation of Rheb and mTOR. We also used 
Perifosine and miltefosine, two alkylphospholipids, which have been shown to 
inhibit AKT(27). Perifosine is currently in clinical trials for solid tumors(28).  Lastly, 
we evaluated a novel, orally bioavailable, dual inhibitor of PI3K and mTOR, NVP-
BEZ235 (Novartis) (Figure 1). 
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The glitazones inhibit PEL growth in vitro 
 
Ciglitazone and rosiglitazone are anti-diabetic compounds belonging to 
the thiazolidenedione class of drugs.  Both activate AMPK via activation of 
PPARγ and adiponectin(7, 29, 30). We treated PEL cell lines with either 100 mM 
of ciglitazone or 150 mM and 200 mM of rosiglitazone for 96 hours(31), to 
determine the sensitivity of these compounds.  
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Figure 2: Inhibition of PEL cell proliferation induced by ciglitazone and rosiglitazone as 
measured by MTS assay. Shown in each panel (y-axis) is the absorbance at 490 nm in 
vehicle (DMSO) without drug ♦) or presence of 100µm ciglitazone (A-D, ■) or 150µm (E-
F, ■) or 200µm rosiglitazone (E-F, ●) versus time in hours after drug treatment (x-axis). 
Each data point is the average of triplicate or quadruplicate measurements. Error bars 
represent the SD and in most cases, are smaller than the symbol.  
Cell viability was measured using the MTS assay. Four different PEL cell 
lines treated with ciglitazone or rosiglitazone showed decreased viability 
compared to vehicle (DMSO) treated cells. Both 100mM ciglitazone and 200mM 
rosiglitazone displayed similar growth-inhibitory effects on BCLM and VG-1 
(approximately four- and five-fold respectively).  The inhibitory effects of 
ciglitazone were greater on BCLM and VG-1 than on BCBL-1 and BCP-1 (Figure 
2).  This reduced sensitivity to ciglitazone may be a consequence of p53 
mutations in BCBL-1 and BCP-1(32), which could prevent phosphorylated AMPK 
from exerting its full inhibitory effect. Indeed, a previous report showed that the 
stabilization and activation of AMPK induces p53-dependent apoptosis(33).  
AMPK phosphorylation was increased upon treatment of the PEL lines with either 
100mM ciglitazone or 200mM rosiglitazone (Figure 3A) indicating that these 
compounds activated their target. As expected, there was a corresponding 
decrease in the phosphorylation of mTOR and its downstream targets, S6K, as 
well as S6 itself (Figure 3A).   
Rosiglitazone delays PEL tumor growth in vivo 
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To investigate the effect of rosiglitazone on PEL growth in vivo, BC-1 cells 
were subcutaneously injected into NOD-SCID mice in the presence of growth 
factor-depleted Matrigel(10). 
 
Figure 3. Effect of glitazone treatment on cellular signaling pathways and tumors in 
mice. A) Immunoblot analysis of protein extracts from the indicated cell lines 
exposed to DMSO (-) or 200 mM rosiglitazone for 72 h, or 100 mM ciglitazone for 96 
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h was performed to visualize the expression of phosphorylated AMPK (Ser172), 
mTOR (Ser 2448), S6K (T421/S424) or S6 (S235/236) proteins along with total S6 
and b-actin as loading controls. B) Decrease in the average tumor size in mice 
treated with rosiglitazone compared to those treated with methyl cellulose (vehicle). 
Volumes of tumors in mice treated with either methyl cellulose as vehicle (n=5), 30 
mg/kg of rosiglitazone (n=5), or 60 mg/kg of rosiglitazone (n=5), are plotted on the y-
axis versus time in days post inoculation on the x-axis. Error bars indicate the 
standard deviation for each group of animals. C) Increase in phospho-AMPK 
(pAMPK; T172) and decrease in phospho-S6K (pS6K; T421/S424) in mouse 
xenograft tumors upon treatment with rosiglitazone.   Immunohistochemistry of 
mouse xenograft tumors using antibodies specific for pAMPK and pS6K is shown. 
No staining was observed in the absence of a specific primary antibody (no 
antibody). Pictures are shown at 400X magnification.  
 
Upon development of palpable tumors, the animals were randomized into 
groups of five and treated five days a week for the duration of the experiment 
with either 0.25% methyl cellulose (vehicle), or with 30 mg/kg or 60 mg/kg 
rosiglitazone suspended in methyl cellulose via oral gavage similar to previous 
reports(8). The animals were sacrificed after 14 days and tumors were harvested 
and measured. Both doses of rosiglitazone delayed tumor growth to some extent 
(Figure 3B), however the differences were not statistically significant. 
Immunohistochemistry showed that AMPK phosphorylation at Thr172 was 
increased in the rosiglitazone-treated mice compared to vehicle-treated mice 
(Figure 3C). S6K, a downstream effector of mTOR, was uniformly 
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phosphorylated at Thr421/Ser424 and detectable in tumors in mice treated with 
the vehicle (methylcellulose), but was virtually undetectable in tumors from mice 
treated with rosiglitazone (Figure 3C). This suggests that rosiglitazone delays 
tumor growth via activation of AMPK and inhibition of protein translation through 
mTOR. 
Miltefosine and perifosine target AKT and inhibit proliferation of PEL in 
vitro 
Miltefosine and perifosine are alkylphospholipids that inhibit activation of 
AKT(27). We treated BCLM, VG1, BC1 and BCBL-1 PEL cell lines with 10, 20, 
30, 40 and 50 mM of miltefosine or perifosine over a 3-day period(27, 34). Figure 
4A shows a representative MTS experiment using the VG-1 cell line and both 
drugs. perifosine was a more potent inhibitor of PEL growth compared to 
miltefosine at all concentrations. Perifosine treatment inhibited AKT and its 
downstream pro-apoptotic targets, FOXO1 and GSK-3β, comparable to the 
levels of the PI3K inhibitor, LY294002(13). The protein translation arm of the AKT 
pathway was also inhibited, as phosphorylation of mTOR (Ser2448), S6K 
(Thr421/Ser424), and the S6 ribosomal subunit (Ser235/236) were decreased 
(Figure 4B).  
Miltefosine and Perifosine delay PEL tumor progression in vivo 
We subcutaneously injected NOD-SCID mice with BC-1 cells suspended 
in growth factor-depleted Matrigel. Upon formation of palpable tumors, mice were 
randomized into groups of five, and injected intra-peritoneally five days a week 
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with 50 mg/kg of either miltefosine or perifosine dissolved in PBS, or equivalent 
volume of vehicle (PBS). Both miltefosine and perifosine inhibited the growth rate 
of tumors compared to vehicle-treated mice (Figure 4C). By day 14 post-
treatment, there was an approximately 50% decrease in average tumor volume 
in perifosine- and miltefosine-treated mice, as compared to vehicle-treated mice 
(p<0.04). Tumor growth was also significantly retarded (p<0.04 for perifosine and 
p≤0.055 for miltefosine by linear mixed effects model analysis). 
Immunohistochemical analyses (Figure 4D) displayed an overall reduction in 
staining for phosphorylated ribosomal S6 protein in tumor sections from 
miltefosine- and perifosine-treated mice compared to the PBS treated mice. This 
reduced phosphorylation correlated with the delay in tumor progression in drug-
treated animals. Sections that were not incubated with primary antibody showed 
no phosphorylated S6 staining (Figure 4D). 
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Figure 4. Effects of alkylphospholipids on PEL. A) Inhibition of PEL cell 
proliferation induced by miltefosine (right panel) and perifosine (left panel) as 
measured by MTS assay. Shown in each panel is the absorbance at 490 nm (y-
axis) in the absence of drug (gray circles) or increasing, indicated doses of either 
miltefosine or perifosine, ranging from 10 mM to 50 mM. Treatment time is 
represented on the x-axis. Each datapoint is the average of triplicate or 
quadruplicate measurements. Error bars represent the standard deviation and in 
most cases are smaller than the symbol. B) Immunoblot analysis of extracts 
harvested from indicated PEL cell lines treated with DMSO (vehicle), the 
indicated drug, or untreated cells (-). Membranes were probed with antibodies 
raised specifically against the phosphorylated forms of FOXO1, GSK3b, mTOR, 
S6K or S6 proteins. Membranes were probed with anti-Actin antibody, as a 
loading control. C) Tumor progression is delayed in miltefosine-treated mice, and 
significantly delayed in perifosine-treated mice. Mice were treated with 50 mg/kg 
of miltefosine (n=5), perifosine (n=5) or vehicle (n=5) by intra-peritoneal injection, 
and followed for 20 days after formation of palpable tumors. Error bars indicate 
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the standard deviation for each group of animals. D) Tumors excised from 
miltefosine- and perifosine-treated mice display decreased phosphorylation of the 
ribosomal S6 protein, compared to vehicle controls. Staining is not observed in 
sections not incubated with primary antibody. Images are shown at 400X 
magnification. 
 
NVP-BEZ235 treatment inhibits proliferation of PEL cell lines in vitro.  
NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative compound shown to 
inhibit PI3K and mTOR kinase activity both in vitro and in vivo(35, 36). NVP-
BEZ235 inhibits the activity of these two kinases by binding, reversibly and 
competitively, to the ATP-binding cleft, thereby preventing phosphorylation and 
activation of downstream targets(10).  We treated BCBL-1, BCP-1, BC-1 and 
VG-1 PEL cell lines with either 50 or 100 nm of NVP-BEZ235 and compared cell 
proliferation of drug-treated or mock-treated cells over a 36-hour time period 
using the MTS assay. Notably, BCBL-1 cells show partial resistance to 50 nm 
rapamycin,(10) yet the same cells remain sensitive to the dual inhibitor. Figure 
5A shows representative cell proliferation profiles of the above-mentioned PEL 
cell lines. The concentration of NVP-BEZ235 required for inhibiting PEL cell 
proliferation by 50% was 5.68 ± 1.76 nm (Figure 5B) for the BC-1 cell line. The 
low inhibitory concentration of NVP-BEZ235 confirms the usefulness of this 
compound as a treatment for PEL, and suggests a favorable pharmacokinetic 
profile. We also performed MTS assays using a combination of 30µM perifosine 
and 50nm NVP-BEZ235 against PEL (Supplemental Figure 1). As expected, 
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because NVP-BEZ235 inhibits PI3K upstream of AKT, the combination of the 
AKT inhibitor perifosine and NVP-BEZ235 did not significantly affect BC-1 
proliferation compared to NVP-BEZ235 alone. 
To confirm the efficacy of NVP-BEZ235 against downstream targets of 
PI3K and mTOR, we tested the phosphorylation status of the downstream targets 
of these two kinases, using western blot analysis (Figure 5C). Treatment with 
NVP-BEZ235 for 24 hours induced marked reduction in phosphorylated mTOR 
(Ser2448) and FOXO1 (Ser256), both targets of the kinase activity of PI3K/AKT. 
Reduced phosphorylation of S6K (Thr421/Ser424), and the ribosomal S6 protein 
(Ser235/236), both targets of mTOR, reflects inhibition of mTOR by NVP-BEZ235. 
Importantly, reduction in the phosphorylation of AKT at Ser473, a feedback 
phosphorylation substrate of mTORc2, indicates that NVP-BEZ235 also inhibits 
mTORc2 activity (Figure 5C)(10). Thus, dual inhibition of PI3K and mTOR likely 
contributes to decreased cell proliferation by NVP-BEZ235.  
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Figure 5. Low doses of NVP-BEZ235 inhibit the downstream targets of PI3K/mTOR 
pathway. A) Inhibition of proliferation of the indicated PEL cell lines upon treatment 
with NVP-BEZ235 as measured by MTS assay. Shown in each panel is the 
absorbance at 490 nm (y-axis) in the absence of drug (gray circles) or increasing, 
indicated doses of NVP-BEZ235. Treatment time is represented on the X-axis. Each 
datapoint is the average of triplicate or quadruplicate measurements. Error bars 
represent the standard deviation and in most cases are smaller than the symbol.  B) 
The IC50 curve for NVP-BEZ235 showing an IC50 value of 5.68 ± 1.76 nm for BC-1 
PEL cells. C) Immunoblot analysis of extracts harvested from indicated PEL cell 
lines treated with DMSO (vehicle) or increasing doses of NVP-BEZ235. Membranes 
were probed with antibodies raised specifically against the phosphorylated forms of 
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AKT (Ser473), mTOR, S6K, pS6, FOXO1 and GSK3β. Membranes were probed 
with anti-Actin antibody, as a loading control.  
Dual Inhibition of PI3K and mTOR in PEL tumor progression in vivo 
We subcutaneously injected NOD-SCID mice with BC-1 PEL cells 
suspended in growth factor-depleted Matrigel as described above. Upon 
formation of palpable tumors, mice were randomized to receive either orally 
administered 40 mg/kg of NVP-BEZ235 (n=7) or vehicle (n=6) five days a week. 
NVP-BEZ235 significantly inhibited the growth rate of tumors compared to 
vehicle-treated mice (Figure 6A). Following drug administration, NVP-BEZ235-
treated mice displayed tumors with significantly smaller volumes compared to 
vehicle-treated mice (p<0.0009 by Linear mixed-effects model analysis). 
Immunohistochemical analyses of tumors derived from NVP-BEZ235-treated 
mice displayed an overall reduction in staining for phosphorylated ribosomal S6 
(Ser235/236) protein and phosphorylated AKT (Ser473), compared to tumors 
from vehicle-treated mice (Figure 6B). Reduced phosphorylation of the S6 
ribosomal protein suggests a reduction in protein translation, leading to delayed 
tumor progression in NVP-BEZ235-treated mice. Reduced phosphorylation of 
AKT at Ser473 confirms the inhibition of mTOR, which can phosphorylate AKT at 
Ser473 via the rapamycin-insensitive mTORc2 complex (Figure 6B).  
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Figure 6. Treatment with NVP-BEZ235 delays tumor progression in vivo in a 
xenograft model of PEL. A) Tumor progression is significantly delayed (p<0.0009) in 
mice treated with 40 mg/kg NVP-BEZ235 administered by oral gavage. Mice were 
treated five times per week with NVP-BEZ235 (n=7) or vehicle (n=6) after the 
development of palpable tumors. Mice were followed for 20 days, at which point 
vehicle-treated mice were euthanized. NVP-BEZ235-treated mice had significantly 
smaller tumors. Error bars indicate the standard deviation for each group of animals. 
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B) Immunohistochemical analyses reveal decreased phosphorylation of ribosomal 
S6 protein and AKT (Ser473) in NVP-BEZ235 treated mice. No staining was 
observed in sections that had not been incubated with specific antibodies. C) 
PI3K/AKT inhibition induces apoptosis in PEL. 1X106 BC-1 PEL cells were treated 
with either 50 µM miltefosine, 50 µM perifosine, or 20 nm NVP-BEZ235, and the 
appropriate vehicle controls. Cells were harvested and lysed 12 hours later. 
Equivalent micrograms of cell lysate for all samples were incubated with a 
fluorogenic caspase-3 substrate (DEVD-AFC). Caspase-3 cleavage of the 
fluorescent DEVD substrate was measured on a fluorometer. The percent of 
caspase-3 activity in BC-1 cells after incubation with perifosine, miltefosine or NVP-
BEZ235 was calculated compared to vehicle treated cells. Percent increase in 
caspase-3 activity of drug treated cells compared to the respective vehicle control 
treated cells is displayed on the y-axis, and the specific inhibitor is shown on the x-
axis. 
PI3K/AKT inhibition triggers apoptosis in PEL cells 
Activation of the PI3K and AKT kinases is important for cell survival. Since 
the inhibition of PI3K/AKT is known to induce apoptosis, we analyzed the levels 
of active caspase-3 in PEL treated with the AKT inhibitors, miltefosine or 
perifosine, and the PI3K inhibitor, NVP-BEZ235. BC-1 cells were treated with 
50µM miltefosine, 50µM perifosine, 20nm NVP-BEZ235, or their respective 
vehicle controls for 24 hours. Cells were harvested and equivalent amount of cell 
lysates were measured for caspase-3 enzymatic activity as a marker of apoptosis. 
We found that NVP-BEZ235-treated BC-1 cells displayed substantially higher 
levels of activated caspase-3 compared to miltefosine- and perifosine-treated 
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cells (Figure 6C). The enhanced ability of NVP-BEZ235 to induce caspase-3-
mediated cell death may explain why NVP-BEZ235 shows higher activity against 
PEL in vitro and in vivo.  We also performed trypan blue staining to determine the 
number of live versus dead cells in PEL treated with 200µM Rosiglitazone, 50µM 
perifosine, 50µM miltefosine or NVP-BEZ235 (10 and 100nm) for various 
timepoints. We found that after a 24-hour drug treatment, NVP-BEZ235 and 
perifosine were more cytotoxic to PEL cells than rosiglitazone (Supplemental 
Figure 2). 
Rosiglitazone, perifosine, and NVP-BEZ235 change the cytokine profile of 
PEL 
PEL are highly sensitive to inhibition of autocrine growth factor signaling 
pathways(37). The cytokines IL-6 and IL-10, are particularly important for PEL 
growth(37), and our group has demonstrated that suppression of IL-6 and IL-10 
translation by the mTOR inhibitor, rapamycin, inhibits PEL cell proliferation. We 
investigated the cytokine expression levels of the PEL cell line BC-1 using a 30-
plex Luminex bead array technology (Figure 7). BC-1 PEL cells secrete high 
amounts of IL-6, IL-10, IP-10/CXCL10, hepatocyte growth factor (HGF), 
MIG/CXCL9, and vascular endothelial growth factor (VEGF). Treatment with the 
PI3K/mTOR dual inhibitor NVP-BEZ235 profoundly decreased secretion of all 
these cytokines (p<0.001 by post-hoc Tukey test), whereas miltefosine, 
Perifosine and rosiglitazone did not significantly alter the cytokine profile of PEL 
cells. Following NVP-BEZ235 treatment for 72 hours, IL-6 and IL-10 levels were  
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80% lower than vehicle control treated cells. Perifosine reduced IL-6 levels to 
50% of control, whilst minimally altering IL-10 secretion. Levels of VEGF, 
MIG/CXCL9, HGF, and IP-10/CXCL10 were decreased between 50-70% by the 
dual inhibitor NVP-BEZ235 compared to the control, but were virtually unaffected 
by either perifosine or miltefosine. Interestingly, NVP-BEZ235 also reduced the 
transcript levels of some of the cytokines, such as VEGF (data not shown).  
Activation of PI3K has previously been shown to regulate VEGF transcription(38), 
and hence dual inhibition of PI3K and mTOR likely affects both mRNA transcript 
and protein levels of some of these cytokines. Curiously, rosiglitazone 
dramatically reduced the levels of IP-10 and HGF similar to that seen with NVP-
BEZ235 treatment, without affecting the secretion levels of any other assayed 
cytokines. The difference in cytokine profile expression between NVP-BEZ235- 
treated cells and those treated with the other inhibitors, separates the in vitro 
proliferation inhibition phenotype from the tumor growth inhibition seen in vivo. 
Although all the inhibitors could prevent proliferation in vitro, NVP-BEZ235 was 
most efficacious at inhibiting tumor growth in vivo, likely due to the inhibition of 
multiple autocrine and paracrine growth factors. This suggests that cytokine 
profiling can be used to differentiate between different PI3K/AKT/mTOR pathway 
inhibitors. 
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Figure 7. Profile of cellular cytokine levels following inhibition of PI3K/AKT/mTOR 
pathway members. IL-6, IL-10, IP-10, HGF, MIG and VEGF levels upon treatment 
with indicated compounds, or with vehicle control are displayed. Changes in 
cytokine levels are represented as percent change from vehicle-treated levels, 
which were set to 100%. Error bars indicated standard deviation. The PI3K/mTOR 
dual inhibitor NVP-BEZ235 dramatically reduces levels of the indicated cytokines 
secreted into the growth medium (p<0.001 by Tukey post-hoc test).  
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DISCUSSION 
 We, and others, have previously shown that individual KSHV viral proteins 
like K1 and vGPCR activate the PI3K/AKT pathway in B cells and endothelial 
cells(12-16). KSHV-infected PEL also display constitutive high-level activation of 
the PI3K/AKT/mTOR pathway(10). Our findings indicate that inhibiting the 
PI3K/AKT/mTOR pathway is an effective modality for treating PEL.  
We determined that the glitazone class of drugs, which are known to 
activate AMPK, have limited efficacy. Ciglitazone and rosiglitazone induced 
dose-dependent inhibition of PEL growth in vitro. This correlated with AMPK 
activation and mTOR inhibition. Although effective in culture, AMPK activation by 
rosiglitazone only marginally reduced tumor growth in a xenograft model of PEL.  
 Miltefosine and perifosine are direct inhibitors of AKT. Both induced dose-
dependent inhibition of PEL in culture, and also inhibited the downstream targets 
of AKT, such as mTOR, leading to reduced phosphorylation and activation of 
S6K and S6. Importantly, they also inhibited AKT targets that are not part of the 
mTOR pathway e.g. FOXO1, and are therefore expected to have a greater 
therapeutic impact than mTORc1 inhibitors alone. In our PEL xenograft model, 
perifosine reduced tumor volume and growth to a statistically significant extent, 
compared to vehicle treated mice. These two compounds therefore warrant 
further study for the treatment of PEL. 
 The dual PI3K/mTOR inhibitor, NVP-BEZ235(35, 36), was more effective 
than compounds that targeted only a single member of the PI3K/AKT/mTOR 
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pathway. Our results demonstrate that the PI3K/mTOR dual inhibitor, NVP-
BEZ235, effectively inhibited the proliferation of PEL cell lines in vitro at a very 
low IC50 of 5.68 ± 1.76 nm.  
NVP-BEZ235 efficacy was comparable across all PEL cell lines tested, 
even those that showed partial resistance to rapamycin(10), and was 
independent of p53 mutation status. BCBL-1, BC-1, BCP-1 and VG-1 showed 
comparable inhibition of proliferation suggesting that dual inhibition of PI3K and 
mTOR negates any survival advantage conferred by p53 mutations present in 
PEL cell lines.  
The selective activity of NVP-BEZ235 on PI3K and mTOR was 
demonstrated by reduced phosphorylation of their downstream targets. Reduced 
phosphorylation of FOXO1 and GSK3b, the downstream targets of AKT, 
confirmed the inhibition of PI3K, whereas reduced phosphorylation of S6K and 
ribosomal S6 confirmed inhibition of mTOR. Importantly, there was an inhibition 
of phosphorylation of AKT at Ser473. This site is phosphorylated by the 
rapamycin-insensitive mTORc2, which is responsible for activating AKT in a 
feedback loop and has been implicated in rapamycin failure after prolonged 
treatment(39, 40). NVP-BEZ235 can prevent this feedback loop. 
NVP-BEZ235 significantly (p<0.009) reduced tumor growth in our PEL 
xenograft model. Tumors excised from NVP-BEZ235-treated mice displayed 
reduced phosphorylation of both ribosomal S6 protein and AKT (Ser473), 
confirming in vivo inhibition of its targets. Importantly, this compound is orally 
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bioavailable, making it an attractive therapeutic molecule. Furthermore, NVP-
BEZ235 treatment induced higher levels of apoptosis in PEL cells, as measured 
by caspase-3 activity, compared to the other PI3K/AKT inhibitors. 
PEL is characterized by elevated IL-6 and IL-10 cytokine secretion(37). 
Our group has previously demonstrated that IL-10 may be used as a prognostic 
marker of PEL, and we have demonstrated that rapamycin treatment reduces IL-
6 and IL-10 secretion in culture and in vivo(10). Using Luminex bead-based 
technology, we investigated the secretion profile of many cytokines following 
treatment with each of the compounds described in this study, or with the 
appropriate vehicle control. Six cytokines (IL-6, IL-10, IP-10, HGF, MIG and 
VEGF) were secreted to high levels in the growth medium of BC-1 cells 
consistent with earlier observations(41, 42). NVP-BEZ235 dramatically reduced 
secretion of all these cytokines 72 hours post-treatment. The other AKT/mTOR 
pathway inhibitors exhibited weaker, more differential phenotypes. Rosiglitazone 
significantly reduced secretion of IP-10 and HGF, but only modestly decreased 
IL-10 secretion, whereas all other cytokine profiles remained unaltered. The AKT 
inhibitor, perifosine, reduced IL-6 secretion by fifty percent, and that of IL-10 by 
twenty percent.   
Only NVP-BEZ235 inhibited vascular endothelial growth factor (VEGF). 
VEGF is an angiogenic growth factor that is involved in tumor proliferation(43). 
Hepatocyte growth factor (HGF) has been implicated in tumorigenesis of 
diffused-large B cell lymphomas (DLBCL) and has been shown to activate AKT 
through PI3K(44). CXCL10/IP-10 and CXCL9/MIG are chemokines that attract T 
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lymphocytes and appear to antagonize angiogenesis(45). However, these 
chemokines also play a role in B lymphocyte migration and dissemination(46). 
Additionally, unlike normal B lymphocytes, Hodgkin lymphoma and several 
different types of NHL, including chronic lymphocytic leukemia, small lymphocytic 
lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, and mantle cell 
lymphoma(47, 48)  have been reported to express CXCL9/MIG and CXCL10/IP-
10, and their cognate receptor CXCR3 as part of an autocrine loop. We surmise 
that these cytokines, chemokines, and growth factors play an important role in 
NHL in general, and that our results may therefore be applicable to other NHL 
beyond PEL. 
In conclusion, the PI3K/AKT/mTOR axis is an important target in NHL 
because it regulates cell survival, protein translation, and as we show here, 
cytokine production. Dual inhibition of the PI3K and mTOR kinases inhibits the 
translation and secretion of the essential paracrine and autocrine cytokines 
required for growth. This is in addition to cell-intrinsic mTOR targets such as Myc 
and Cyclin D1(49). Inhibition of these cytokines is required for inhibiting PEL 
tumor growth in vivo. Thus, this dual inhibitor may prove therapeutic for tumors 
that are critically dependent on autocrine and paracrine growth factors for their 
survival. 
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CHAPTER 3 
DYSREGULATION OF FATTY ACID SYNTHESIS AND GLYCOLYSIS IN NON-
HODGKIN LYMPHOMA4 
 
INTRODUCTION 
 Primary effusion lymphoma (PEL) is a subtype of B cell non-Hodgkin 
lymphoma (B-NHL), which has a poor prognosis, with a median survival time of 
six months (1). PEL display elevated levels of activated phosphatidylinositol 3-
kinase (PI3K), AKT and mammalian target of rapamycin (mTOR) kinases (2).  All 
PEL are infected with Kaposi sarcoma-associated herpesvirus (KSHV) and 
hence represent a tightly defined sub-type of B-NHL. In addition to PEL, KSHV is 
also associated with Kaposi sarcoma (KS) and multicentric Castleman’s disease 
(MCD) (3, 4). Our group and others have previously shown that KSHV viral 
proteins such as K1 and vGPCR can activate the PI3K/AKT/mTOR pathway in B 
lymphocytes and endothelial cells (5-9) and that the reliance of PEL on the 
PI3K/AKT/mTOR pathway can be exploited to treat PEL using inhibitors of this 
pathway (2, 10).  
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 The ability of cancer cells to selectively induce aerobic glycolysis in order 
to generate ATP was first reported by Otto Warburg (11). Glycolysis generates 
fewer ATP per molecule of glucose compared to oxidative phosphorylation, and 
produces lactate, which is excreted (Fig. 1A). Recent studies indicate that 
upregulated aerobic glycolysis in cancer cells exerts a protective effect against 
apoptosis (12). Moreover, the requirement for high rates of macromolecular 
synthesis required by rapidly proliferating cancer cells is met by upregulating 
glycolysis (13). 
 The PI3K/AKT/mTOR signaling pathway is essential for the control of cell 
proliferation and protein translation, and also regulates anabolic activities within 
the cell (14). PI3K/AKT signaling is known to regulate glycolysis by controlling the 
expression and localization of the glucose transporter GLUT1 (15), hexokinase, 
and transcriptional control of glycolytic enzymes (16). PI3K activation results in 
PDK1 and subsequently AKT activation, which is necessary for the induction of 
glycolytic enzymes (17-19). AKT also activates the mTOR signaling complex, 
which regulates protein translation. Under nutrient abundant conditions, mTOR 
activation stimulates aerobic glycolysis as well as de novo lipid synthesis, 
mediated via mobilization of the SREBP group of transcription factors (20). 
SREBP1 can induce the transcription of fatty acid synthase (FASN), which is a 
multi-enzyme complex responsible for synthesizing cellular lipids. FASN is 
expressed in the liver, and present at low levels in other tissues. Many human 
cancers express high levels of FASN (21, 22), and FASN is posited to be a 
metabolic oncogene (23). Moreover, aberrant PI3K signaling resulting from 
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receptor tyrosine kinase hyperactivation in cancer cells has been demonstrated 
to drive FASN expression via constitutive SREBP-1c activity (24, 25). 
 In this work, we describe the metabolic sequelae of PI3K/AKT/mTOR 
pathway activation on the metabolism of B-NHL, with a focus on PEL. We 
demonstrate that most B-NHL, including PEL are highly glycolytic and actively 
synthesize fatty acids, compared to healthy donor-derived primary B cells. 
Further, we demonstrate that PEL display elevated levels of FASN compared to 
primary B cells, and that the glycolysis and FAS pathways in PEL are interlinked, 
and dependent on PI3K/AKT/mTOR activation.   
 
MATERIALS  & METHODS 
Cell isolation and culture 
Primary B cells were isolated by negative selection from donor buffy coats 
using the B cell isolation kit II (Miltenyi) as per the manufacturer’s directions. 
Cells were cultured at 37°C with 5% CO2 in filter-sterilized RPMI-1640 
supplemented with 10% FBS, 100 U/ml each of penicillin and streptomycin, 
0.075% nahco3 and 0.05 mm 2-mercaptoethanol. Purity of the isolated B cells 
was determined by staining with phycoerythrin-conjugated anti-CD19 antibodies 
(Miltenyi) and analyzed on a macsquant® VYB (Miltenyi). Purity ranged from 89-
98% (data not shown). Primary effusion lymphoma (PEL) cell lines were cultured 
in identical media and culture conditions as previously described (26). 
Lymphoblast cell line were generated by infecting freshly isolated primary human 
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B cells with Epstein-Barr virus (EBV), using previously described protocols (27). 
Follicular lymphoma cells were cultured as previously described (28). CA46, a 
Burkitt lymphoma cell line, was purchased from ATCC and maintained in RPMI-
1640 supplemented with 20% FBS and 100 U/ml penicillin and streptomycin. All 
cell lines were cultured in PEL growth medium for every experiment.  
Chemical compounds 
2-deoxy-D-glucose (2DG), C75 and lipopolysaccharide (LPS) were 
purchased from Sigma Aldrich. LY294002 was purchased from Calbiochem. 2DG 
was suspended in H2O, C75 and LY294002 in DMSO, and LPS in phosphate-
buffered saline. All cells were treated for indicated time periods. For visualizing 
intracellular lipids, the lipophilic dye Nile Red (AAT Bioquest), was used per the 
manufacturer’s direction. A Nikon Eclipse Ti microscope equipped with NIS 
Elements imaging software was used to acquire images. 
Cell Viability Assays 
To determine the susceptibility of both cell types to various inhibitors, 2 x 
105 PEL or primary B cells were cultured in growth medium containing 
compounds at increasing concentrations, or the appropriate vehicle controls, for 
indicated lengths of time. Cell viability was determined in quadruplicate by trypan 
blue exclusion. Proliferation was measured using the Cell Titer 96Aqueous One 
Solution (Promega) and apoptosis was measured using the ApoAlert Caspase-3 
assay (Clontech), both according to the manufacturer’s instructions, and 
absorbance was measured using a Fluostar OPTIMA (BMG Labtech) plate 
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reader. Additionally, cell viability was also measured using forward and side 
scatter parameters from flow cytometry performed on a MACSquant® VYB 
(Miltenyi).  
Immunoblotting 
Following indicated treatments, cells were washed with ice-cold PBS and 
then lysed in a buffer containing 150 mm NaCl, 50 mm Tris-HCl (ph 8), 0.1% 
NP40, 50 mm NaF, 30 mm β-glycerophosphate, 1 mm Na3VO4, and 1× Complete 
Protease Inhibitor cocktail (Roche Diagnostics). Protein concentration was 
determined by Bradford assay, and equal amounts of proteins were separated 
using SDS-PAGE, transferred onto Hybond-ECL nitrocellulose membranes (GE 
Healthcare), blocked and incubated in appropriate antibodies overnight at 4°C. 
The antibodies used were against Fatty Acid Synthase, phospho-AKT Ser473 
(Cell Signal Technology), and Ku 70/80 as a loading control (a generous gift of 
Dale Ramsden, PhD; University of North Carolina at Chapel Hill). Blots were 
incubated in appropriate secondary antibodies conjugated to horseradish 
peroxidase, and bands were visualized using chemiluminescence (GE 
Corporation). Densitometry was performed using NIH Image J. 
Measurement of glycolytic flux 
Glycolytic flux was measured as previously described (29). Briefly, 2 x 106 
cells of each type were incubated with indicated compounds for 72 h, after which 
cells were washed twice in PBS and starved for 30 min by suspension in 
glucose-free Krebs solution, followed by a 1 h pulse with 10 µCi of D-[5-3H](N)-
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glucose (Perkin-Elmer) and non-labeled glucose, adjusted to a final glucose 
concentration of 10 mM. Equal volume of 0.2 M HCl was added to all samples to 
stop the reaction after which [3H]-H2O generated via glycolysis was separated 
from the D-[5-3H](N)-glucose bolus by evaporation-mediated equilibration in 
sealed chambers. Levels of [3H]-H2O were measured on a liquid scintillation 
counter (Wallac), and glycolytic flux was determined by normalizing CPM to the 
total protein input. These and all subsequently described data were analyzed 
using a two-tailed type II Student’s t-test for significance; p values are indicated 
at appropriate locations within figure legends. 
Measurement of lipid synthesis and analysis of newly synthesized lipid 
classes. 
Lipid synthesis was measured as previously described (30). Briefly, 1 X 
106 B cells were incubated with indicated compounds for 72 h; 12 h prior to 
harvest and subsequent analysis, growth medium of all cells was supplemented 
with D-[U-14C6]-glucose, after which cells were collected, washed thrice with PBS 
and then lysed by vortexing in 0.5% NP-40 in water. Lipids were extracted by 
sequentially mixing in 1 ml methanol, 2 x 1 ml ChCl3 and 1 ml H2O, with 
extensive vortexing after addition of each solvent. To resolve aqueous and 
organic phases, tubes were centrifuged for 10 min at 2000 x g in a tabletop 
centrifuge. The organic phase was transferred to a fresh tube and excess chcl3 
was evaporated. Extracted lipids were dissolved in 100 ml of chcl3, and counted 
using scintillation fluid (Scintisafe) in a liquid scintillation counter (Wallac). CPM 
was normalized to the total protein input. Analysis of lipid components was 
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performed by the UNC Nutrition and Obesity Research Center using previously 
described methods (31). 
Measurement of fatty acid oxidation 
Fatty acid oxidative capacity was determined by measuring 1-14C-oleate 
oxidation to CO2 as previously described (32). Briefly, 1 x 106 B cells were 
incubated with indicated compounds for 72 h, after which cells were resuspended 
in normal growth media supplemented with 12.5 mm HEPES (ph 7.4) and 500 
µm 1-14C-oleate (Perkin Elmer) complexed with 0.5% BSA (Sigma) and 
incubated for 2 h at 37°C. A result of 1-14C-oleate oxidation is release of 
radiolabeled bicarbonate into the growth medium, which was collected at the end 
of 2 h and transferred to custom wells. Medium was acidified with HClO4 and 
resulting 14CO2 was captured in 1N NaOH over 1 h and counted using liquid 
scintillation (Wallac). Specific activity was calculated following normalization of 
CPM to protein content.  
Metabolic profiling 
Glycolytic and fatty acid metabolite profiles were obtained to assess the 
relative distribution of various intra- and extracellular metabolites of PEL and 
primary B cells by culturing all cells for three days in growth media described 
above at a starting concentration of 1 x 106 cells/ml, after which cells were 
washed twice in PBS and cell pellets were flash-frozen. The conditioned growth 
media of cultured cells was also collected after centrifugation and flash frozen. 
Further sample preparation, metabolic profiling, peak identification and curation 
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was performed by Metabolon, Inc. (Durham, NC) using previously described 
methods (33).  
Profiling of fatty acid oxidation intermediates 
1 x 107 PEL or primary B cells were cultured for 36 h in growth media 
supplemented with 1 mM L-carnitine, after which cells were placed in fresh media 
containing indicated compounds for a further 72 h. Cells were harvested, washed 
in PBS and then snap-frozen. Cell pellets were resuspended in ddH2O and lysed 
on ice for 15 min, followed by sonication and centrifugation at 13,000 x g for 15 
min at 4°C. Supernatants were quantified for protein concentration and stored at 
-80°C. Profiling of cell lysates by tandem MS was performed as previously 
described (34). 
Bioinformatics 
Hierarchical clustering and principal component analysis was conducted 
using the R programming environment (version 2.13.2) package factominer. 
 
RESULTS 
PEL display elevated aerobic glycolysis 
 To determine the minimum glucose (Glc) requirement of PEL cells, 2 x 105 
PEL cells were cultured in Glc-free media with defined amounts of D-Glc, and 
cell survival was monitored using two independent techniques: trypan blue 
exclusion (Fig. 1B, left panel) and MTS assay (Fig. 1B, right panel). Viability of 
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BCP-1, a representative PEL cell line, decreased when the D-Glc concentration 
of growth medium was lowered, and the reduction in cell viability correlated with 
a dose-dependent decrease in Glc concentration (Fig. 1B). These data were 
similar in other PEL lines tested, including BC-1, BCBL-1, BCLM and VG-1. Thus, 
PEL are dependent on Glc for survival.  
  
 
	   99 
 
 
Figure 1: Glycolysis and fatty acid synthesis pathways. (A) Once glucose (Glc) is 
transported into the cell, hexokinase rapidly phosphorylates Glc into Glc-6-phosphate, 
which participates in glycolysis to generate 2 ATP. Pyruvate, the end product of 
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glycolysis, is converted into lactate by lactate dehydrogenase and is secreted. 
Alternatively, pyruvate can be further oxidized in the mitochondrion via the Krebs 
cycle to yield 36 ATP per molecule of Glc. Citrate, an intermediate metabolite, can 
exit the Krebs cycle and be transported into the cytoplasm, where it can be broken 
down into acetyl-CoA.  Acetyl-CoA is converted into malonyl-CoA by acetyl-CoA 
carboxylase, which is the commitment step of fatty acid synthesis (FAS). Acetyl- and 
malonyl-CoA, in a series of reactions, are combined by Fatty Acid Synthase (FASN), 
a multi-enzyme polypeptide, to yield palmitate (C16), which is then elongated or 
desaturated into other fatty acids. These fatty acids can be used to further synthesize 
other macromolecules and lipids necessary for dividing cells. (B) BCP-1, a 
representative PEL, is sensitive to Glc deprivation from growth medium, which 
normally has 2 mm glucose. Reduction of Glc concentration in growth medium 
reduces BCP-1 proliferation as determined by MTS assay (right panel), and 
increases the percentage of dead cells, as visualized by trypan blue exclusion (left 
panel). (C) BCBL-1, another representative PEL, is susceptible to 2DG added to 
normal growth medium, in a dose-dependent manner. Error bars are ± SEM, and 
data is representative of multiple independent experiments. 
 
 
 
 
 
 
	   101 
 Next, 2 x 105 PEL cells were treated with increasing concentrations of the 
inhibitor 2-deoxy-D-glucose (2DG), a D-Glc mimetic that cannot be metabolized 
by glycolytic enzymes, thereby inhibiting glycolysis. Cells were cultured in fully-
supplemented media, which contains 2 mm D-Glc, containing increasing doses 
of 2DG for 0, 12 or 24 hours and then analyzed by MTS assay. 2DG inhibited the 
proliferation of BCBL-1, a representative PEL, in a dose-dependent manner (Fig. 
1C), indicating that inhibition of glycolysis is sufficient to reduce PEL cell viability. 
 Since PEL are heavily reliant upon Glc, glycolysis was compared between 
PEL and primary B cells. Intra- and extracellular levels of Glc and lactate were 
measured from primary B-lymphocytes isolated from six individual healthy donors 
and six different PEL cell lines: BC-1, BC-3, BCBL-1, BCP-1, JSC-1 and VG-1. 
Averaged intensities of intracellular metabolites were normalized to total cellular 
protein, and extracellular metabolite intensities were normalized to the total 
volume of spent media. When compared to primary B cells, PEL displayed 
decreased levels of intracellular Glc and elevated levels of intracellular lactate 
(Fig. 2A) indicative of upregulated glycolytic flux. Analysis of the spent growth 
media from equivalent numbers of cells revealed higher levels of extracellular 
lactate and pyruvate in the growth medium of PEL cells, compared to primary B 
cells (Fig. 2B). PEL media had a concurrent decrease in extracellular D-Glc, 
confirming enhanced Glc uptake and increased glycolysis in PEL compared to 
primary B cells.   
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Figure 2. PEL upregulate glycolysis.  The protein-normalized relative intensities 
(“scaled intensities”) of intra- and extracellular concentrations of glycolytic 
intermediates, represented as box and whisker plots, is significantly different 
between PEL and primary B cells.  Data is the combined average of six different 
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primary B cells derived from 6 healthy donors and six PEL lines. (A) Intracellular 
levels of free Glc are lower while that of lactate are higher in PEL, as compared to 
primary B cells. (B) The spent media of PEL contains lower concentration of Glc and 
increased levels of lactate and pyruvate compared to the spent media of primary B 
cells. (C) Equal numbers of PEL and primary cells were cultured for 24 h, and 
glycolytic flux was measured. PEL cells exhibit significantly increased (p≤ 0.01)  
glycolysis compared to primary human B cells. (D) Equal numbers of PEL, BL 
(CA46), FL (K422 and SUDHL4) and primary B cells were cultured for 24 h, and 
glycolytic flux was measured. All B-NHL have significantly (p value =0.000627) 
higher glycolytic flux compared to primary B cells. Data are normalized to total input 
protein. Error bars are ± SEM, data is one representative of >5 independent 
experiments. 
 
 We also measured the glycolytic flux of both B-NHL and primary B cells. 
Cells were pulsed with 10 µCi of D-[5-3H](N)-glucose.  [3H]-H2O generated 
through glycolysis was measured, and glycolytic flux was determined by 
normalizing CPM to the total protein input. We found that glycolytic flux was 
significantly increased (p≤0.001) up to four-fold in PEL cells compared to primary 
human B cells; Fig. 2C shows a representative panel of PEL and primary B cells. 
Fig. 2D shows a comparison between two PEL lines BC-1 and BCBL-1, the 
Burkitt lymphoma (BL) cell line CA46, and the follicular lymphoma (FL) lines 
K422 and SUDHL4, in comparison with two primary B cells derived from different 
donors than in Fig. 2C. CA46, K422 and SUDHL4 are all EBV- and KSHV-
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negative.  We found that glycolysis is highly upregulated in all of these B-NHL 
lines, compared to primary B cells.  
Upregulation of fatty acid synthesis (FAS) in PEL 
 Fatty acid synthase (FASN) is a multi-functional protein complex 
responsible for synthesizing all cellular fatty acids. Aberrant FASN over-
expression can be a metabolic signature of some human cancers (21, 23). We 
analyzed equivalent amounts of lysate of various PEL cell lines and primary B 
cells by immunoblotting to compare the relative expression of FASN protein. As 
shown in Fig. 3A, FASN was highly expressed in every PEL cell line analyzed 
(Fig. 3A), while FASN expression was barely detectable in lysates from primary B 
cells. PEL and primary B cells were also stained with the lipophilic dye Nile Red, 
and visualized using fluorescence microscopy (Fig. 4). PEL cells contain many 
cytoplasmic lipid droplets that are absent in primary B cells, indicative of 
intracellular lipid accumulation. To determine whether FASN protein expression 
correlated with activation of fatty acid synthesis (FAS), we determined the rate at 
which de novo FAS occurs in PEL and primary B cells, by measuring the degree 
of incorporation of radiolabeled Glc into the cellular lipid fraction. Radioactive 
counts from the extracted lipid fraction of each cell type were normalized to the 
total protein content of the cell pellet. We found that PEL synthesize fatty acids 
from Glc at a substantially higher rate (p=0.012) compared to primary cells (Fig. 
3B).  
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Figure 3. FAS is a critical and essential metabolic pathway for the proliferation of 
PEL. (A) PEL express higher levels of fatty acid synthase (FASN) compared to 
primary B cells. Ku80 is shown as a loading control. (B) The rate of FAS in PEL is 
significantly higher (p=0.012) compared to primary B cells. (C) PEL (BC-1 and 
BCBL-1) have higher FAS rates compared to BL (CA46) and FL (K422 and 
SUDHL4). Collectively, all B-NHL have a higher FAS rate compared to primary B 
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cells. Data are normalized to total input protein, and is one representative of multiple 
independent experiments. Error bars are ± SEM.  (D) Inhibition of FAS using varying 
concentrations of the FASN inhibitor, C75, leads to a dose-dependent increase in 
cell death in BC-1 and BC-3 PEL cells, as measured by trypan blue exclusion. (E) 
Inhibition of FAS using C75 leads to a small amount of cell death in primary B cells 
from two donors, as measured by trypan blue exclusion. Error bars are ± SEM. 
 
Figure 4: PEL cells display intracellular lipid droplets. BCBL-1 and primary B 
cells were stained with the lipophilic dye, Nile Red. Stained cells were visualized 
using a Nikon Eclipse Ti microscope (Ex/Em = 552/636 nm, or bright field) at 10X 
magnification under identical settings. The Nikon Eclipse is equipped with NIS 
Elements imaging software.  Fluorescence in PEL is attributed to the large 
amount of intracellular lipid, while the primary B cells do not exhibit the same 
degree of fluorescence. 
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 We also compared the FAS rates of other B-NHL cell lines (CA46, K422 
and SUDHL4) to FAS rates of primary B cells (Fig. 3C), and found that 
upregulated FAS is a phenotype shared by all the B-NHL lines we tested, with 
significantly (p= 0.023) elevated FAS rates compared to primary B cells. 
Interestingly, PEL generally exhibited higher rates of FAS compared to the other 
B-NHL tested. 
Increased FAS levels could be a consequence of reduced catabolism or 
increased synthesis. We therefore measured the rate of fatty acid oxidation 
(FAO) using previously described methods (32) and described in the methods 
section.  Fig. 5 demonstrates that FAO rates are not significantly different 
between PEL and primary B cells. Thus, FAS seems to be the dominant fatty 
acid metabolic pathway upregulated in PEL.  
 
Figure 5: FAO levels do not significantly differ between PEL and primary B cells. 
PEL and primary B cells oxidize the radiolabeled fatty acid 14C-Oleate, at similar 
rates. Data is normalized to total input protein and error bars are ±SEM 
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 To establish the importance of increased FAS for PEL survival, we 
inhibited FAS with C75, a FASN inhibitor (35, 36). When treated with increasing 
doses of C75, PEL cells displayed a dose-dependent increase in cell death, as 
measured by trypan blue exclusion (Fig. 3D). BC-1 and BC-3 are shown as 
representative PEL.  In contrast, primary B cells were minimally affected (Fig. 3E). 
Fig. 6A and 6B respectively demonstrate that both Burkitt (CA46) and follicular 
(SUDHL4) lymphoma cell lines are susceptible to C75, however, the degree of 
susceptibility is not as great as that of PEL. FAS inhibition by C75 resulted in 
activation of pro-apoptotic caspase-3 in all B-NHL (Fig. 6C). 
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Figure 6: B-NHL are susceptible to the FAS inhibitor C75. (A) CA46 and (B) 
SUDHL4 B-NHL are susceptible to C75. C75 treatment leads to about 50% 
reduction in proliferation of these two lines, in contrast with >90% cell death of 
PEL, at the same dose (10 µg/ml). (C) C75 induces apoptosis in B-NHL. 
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  B lymphocytes isolated from circulating peripheral blood are 
normally in a resting state. PEL are lymphoma cells, and hence proliferate 
continuously in the absence of specific stimulus. To rule out the possibility 
that differentials in glycolysis and FAS were a consequence of proliferation 
rather than the transformed phenotype, we measured glycolytic flux, FAS 
rates and FASN expression in activated primary B cells. Primary B cells were 
treated for 48h with either PBS as vehicle, or 10 mg/ml lipopolysaccharide 
(LPS) to stimulate B cell proliferation as previously reported (37), after which 
proliferation was confirmed using the MTS assay (Fig. 7A). The rates of 
glycolysis (Fig. 7B) and lipid synthesis (Fig. 7C) were quantified and 
compared to PEL (BC-1 and BCBL-1). LPS-stimulated B cells proliferated 
more than unstimulated B cells, as expected (Fig. 7A and Fig. 8C). This was 
accompanied by a doubling in the rate of glycolysis, although the increased 
glycolytic rate was still significantly lower (p≤0.01) than that of vehicle-treated 
PEL cells (Fig. 7B). Interestingly, LPS-stimulated primary B cells did not 
change their rates of FAS compared to vehicle-treated primary B cells (Fig. 
7C), and this rate of FAS was significantly lower than that of an equivalent 
number of vehicle-treated BC-1 and BCBL-1 PEL cells (p≤0.05). LPS 
stimulation of PEL did not further increase glycolysis or FAS compared to 
vehicle-treated PEL (Fig. 8A and B).   Furthermore,  immunoblot analysis of 
cell lysates revealed that FASN expression in primary B cells was slightly 
increased upon LPS-stimulation (Fig 7D); however, FASN expression in 
stimulated primary B cells was still five-fold lower than that of unstimulated 
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(vehicle-treated) PEL cells. These data suggest that FASN activity is an 
independent phenotype of PEL rather than a consequence of increased 
proliferation index and that upregulated lipid synthesis observed in PEL cells 
is a metabolic signature of PEL. 
 
 
Figure 7. LPS-driven proliferation of primary B cells is not linked to the rate of 
FAS as is evident in untreated PEL. (A) Stimulation of primary B cells with 10 
µg/ml of LPS leads to an increase in proliferation as measured by MTS assay. 
(B) Glycolysis is minimally upregulated in LPS-stimulated proliferating primary B 
cells, but the rates are significantly lower (* indicates p≤ 0.05) than those of 
vehicle-treated PEL. (C)  FAS is not upregulated in LPS-stimulated primary B 
cells and the rates of FAS are significantly lower (* indicates p≤0.01) than those 
seen in untreated PEL. Error bars are ± SEM. (D) There is a slight increase in 
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FASN expression in LPS-stimulated proliferating primary B cells, but these levels 
are 5 times lower than seen in untreated PEL (quantified using densitometry). 
Ku80 is a loading control. 
 
 
Figure 8: LPS-driven proliferation of primary B cells. (A) Glycolysis is minimally 
upregulated in LPS-stimulated primary B cells but the rates are significantly lower 
than those of vehicle-treated PEL. Error bars are ±SEM. (B) FAS is not 
significantly upregulated in LPS-stimulated primary B cells, and the rates of FAS 
are significantly lower than those seen in untreated PEL. Error bars are ±SEM. 
(C) Primary B cells proliferate upon treatment with LPS over a period of 48h, 
whereas PEL cell proliferation remains unchanged post-LPS stimulation. 
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PEL have a distinct lipid synthesis profile compared to primary B cells  
We identified the major classes of lipids resulting from FAS by culturing 
primary B and PEL cells in medium supplemented with D-[U-14C6]-Glc; lipids 
derived from D-[U-14C6]-Glc were identified using thin-layer chromatography, as 
previously described (31). Table 1 demonstrates that the PEL and primary B cells 
have different amounts of de novo synthesized lipids that are derived from Glc. 
We found that phosphatidylcholine, phosphatidylethanolamine, 
phosphatidylinositol, phosphatidylserine and sphingomyelin, the major 
components of eukaryotic cell walls, are preferentially and abundantly 
synthesized by PEL, compared to primary B cells.  Interestingly, PEL cells also 
had high intracellular levels of de novo Glc-derived triglycerides. The ratio of de 
novo lipids and triglycerides synthesized using glucose precursors is much 
higher in PEL compared to primary B cells.  
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Table 1: Summary of 14C-glucose derived lipids, newly synthesized by PEL, 
compared to primary B cells.   
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Table 2: List of scaled PEL and B cell metabolite intensities that were subject to 
hierarchical clustering and principal component analysis.  
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Glycolysis and Fatty Acid Synthesis are intimately linked in B-NHL 
 We measured both glycolytic flux and rates of FAS in an equivalent 
number of both PEL and primary B cells, in the presence of 1 mm 2DG 
(glycolysis inhibitor), or 10 µg/ml C75 (FAS inhibitor) for 72h. As shown in Fig 9A, 
2DG inhibited glycolysis in both cell types, as expected. However, C75 also 
reduced glycolysis to levels similar to that seen following 2DG treatment (Fig.9A). 
In the converse experiment, Fig. 9B demonstrates that while C75 expectedly and 
potently inhibits the rate of FAS, 2DG also reduces FAS in PEL. This suggests 
that Glc is utilized for both glycolysis and FAS in PEL and suggests that 
upregulation of glycolysis is a mechanism to generate intermediates that can be 
used for the synthesis of fatty acids (13, 38). In contrast, the rate of FAS in 
primary B cells remained static and independent of 2DG treatment (Fig. 9B).  In 
PEL, inhibition of FAS decreased the rate of glycolysis, and conversely, inhibition 
of glycolysis blocked FAS. This suggests that both glycolysis and FAS are 
intimately linked in PEL and inhibition of one pathway impacts the other.  
Moreover, these two pathways are linked in other B-NHL subsets as well. Fig. 9C 
demonstrates that FAS inhibition reduces glycolytic flux in the FL cell line, 
SUDHL4, and Fig. 9D indicates that glycolysis inhibition potently reduces FAS 
not only in B-NHL lines, but also in an EBV-positive lymphoblastoid cell line 
(EBV-LCL).  
 Thirty-nine glycolysis and FAS intermediates (listed in Table 1) from five 
PEL cell lines and six primary B cell samples were analyzed and the data were 
subjected to unsupervised clustering (Fig. 9E) and principal component analysis 
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(PCA) (Fig. 9F). PEL and primary B cells clearly segregated into two distinct 
groups as represented in the dendrogram (Fig. 9E) or along component 2 in the 
PCA (Fig. 9F). The dissimilarity between the PEL cluster and the primary B cell 
cluster was much greater than among primary B cell cultures alone or among the 
PEL. 
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Figure 9: Glycolysis and FAS are intimately linked in B-NHL. (A) PEL and 
primary B cells treated for 72 h with 10 µg/mL C75 show a significant decrease in 
glycolysis (P ≤ 0.05 for all comparisons), similar to 1 mM 2DG-treated cells 
(positive control). Error bars are ± SEM. (B) PEL cells treated for 72 h with 1 mM 
2DG have decreased FAS (P ≤ 0.05), and with 10 µg/mL C75 (positive control) 
have significantly decreased FAS (P ≤ 0.05). Primary B cells display minimal 
FAS activity, which is not down-regulated with inhibitors. Error bars are ± SEM; 
data are representative of more than three independent experiments. (C) B-NHL 
(including PEL), LCL, and primary B cells treated for 72 h with 10 µg/mL C75 
show a reduction in glycolysis comparable with 2DG-treated cells. (D) Glycolysis 
inhibition of B-NHL (including PEL) and LCL with 2DG substantially reduces FAS 
to a rate similar to the FASN inhibitor C75, but does not impact FAS in primary B 
cells. (E and F) A dendrogram of hierarchical clustering (E) and principal 
component analysis (F) of relative intensities of metabolic intermediates of 
glycolysis and FAS demonstrates that PEL and primary B cells display distinct 
metabolic profiles. 
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PI3K/AKT is required for increased glycolysis and fatty acid synthesis in 
PEL 
 PI3K/AKT signaling is known to regulate glycolysis, and previous reports 
indicate that PI3K inhibition reduces glycolytic flux and induces cell cycle arrest in 
diffuse large B cell lymphomas (39). We investigated whether inhibiting PI3K 
using LY294002 would alter glycolysis and FAS in PEL. We first determined a 
dose of LY294002 (1 µM) that was not significantly cytotoxic to PEL cell lines 
over the course of 72h (Fig. 9). Next, equivalent numbers of PEL and primary B 
cells were treated with either 1 µM of LY294002 or DMSO for 72h, after which 
the rates of glycolysis and FAS were measured as described above. As expected, 
LY294002 dramatically (p≤0.01) reduced the glycolytic flux in both PEL and 
primary B cells (Fig. 10). We also found that LY294002 significantly (p≤0.05) 
decreased the rates at which PEL cells incorporated radiolabeled Glc into lipids 
via FAS (Fig. 10B). However, the primary B cells were unaffected (Fig. 10B).  
Moreover, as shown in Fig 10C, LY294002 treatment resulted in a dose-
dependent reduction of FASN expression in PEL, as previously reported for 
prostate cancer (40), providing a potential mechanism for the dramatic reduction 
in FAS in PEL upon PI3K inhibition. Collectively, these data indicate that not only 
does PI3K/AKT inhibition in PEL decrease FASN expression, but it also 
diminishes glycolytic flux, thereby preventing Glc incorporation into newly 
synthesized fatty acids. 
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Figure 10: PI3K inhibition of PEL. To determine a non-cytotoxic dose of 
LY294002, the drug was added to cells at different concentrations, ranging from 
10 nM to 50 µM for 72h. Cell death was measured by trypan blue exclusion, and 
represented as percent of total cells counted.  
 
FAS inhibition leads to an accumulation of carnitine.  
 To examine the degree of FAO efficiency within B cell lymphomas and 
primary B cells, we compared the relative distribution of FAO intermediates 
derived from PEL (BC-1, JSC-1 and VG-1) and primary B cells from two healthy 
donors. All data are normalized to protein content and are shown in Fig. S6A, B, 
C. The overall levels of free carnitine are lower in PEL compared to primary B 
cells (Fig. 10A). Lowered carnitine levels in colon cancer cells have been shown 
to inhibit the generation of apoptosis-inducing O2- radicals (41). Treatment of PEL 
and primary B cells with the FAS inhibitor C75 resulted in a decrease in cellular 
free carnitine in both cell types, however, the magnitude of reduction was greater 
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in PEL (31% reduction) compared to primary B cells (13.5% reduction), which 
might reflect the fact that PEL are more sensitive to C75 than primary B cells.  
We also measured the relative levels of distinct acyl-carnitine 
intermediates of FAO by MS.  We found that many of the even-chained acyl-
carnitines were increased in PEL compared to primary B cells (Figs. S6B and 
S6C), indicative of incomplete oxidation of fatty acids (34). In contrast, primary B 
cells display higher amounts of C3 and C5 acyl-carnitines, which suggest a 
reliance on oxidation of amino acids rather than fatty acids (34). 
 
Figure 11: Levels of free carnitine and FAO intermediates differ between PEL 
and primary B cells. (A and B) Tandem mass spectrometric analysis was used to 
determine the relative intensities of carnitine and acyl-carnitine intermediates 
within PEL and primary B cells. (A) Levels of free carnitine (normalized to total 
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cellular protein) in PEL are slightly lower than in primary B cells. Two different 
primary B-cell donors were combined for this analysis. FAS inhibition with C75 
(open bars) decreases free carnitine in both PEL and primary B cells, however, 
the magnitude of decrease is greater in PEL compared with primary B cells. (B 
and C) Relative distribution of intracellular acyl-carnitines reveals that PEL (black 
bars) have higher levels of even-chained acyl-carnitine intermediates compared 
with primary B cells (gray bars). Further, higher levels of C3 and C5 acyl-
carnitine intermediates are found in primary B cells compared with PEL (Fig 11 
B).   
 
Combination of LY294002 and C75 is most effective at inhibiting PEL 
proliferation 
  Overall, our findings suggest that FAS is upregulated in PEL and other B-
NHL. The above experiments indicate that the PI3K inhibitor, LY294002, blocks 
glycolysis and FAS in PEL (Fig. 10). Therefore we sought to determine whether a 
combination of LY294002 and C75 would enhance PEL cell death. We treated 
PEL cells with increasing doses of LY294002 and C75 for 72h, and measured 
cell survival by trypan blue exclusion.  As seen in Fig. 12, either drug alone 
reduced cell viability in a dose-dependent manner. However, combined treatment 
with 10 µM LY294002 and 10 µg/ml of C75 led to death of approximately 75% of 
PEL cells (p≤0.05) in culture. These data confirm that FAS inhibition may be an 
efficacious treatment modality for PEL, particularly when combined with existing 
PI3K-targeted chemotherapeutics. 
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Figure 12: FAS inhibition increases susceptibility of PEL to the PI3K inhibitor 
LY294002. PEL are sensitive to LY294002 in a dose-dependent manner, as 
measured by trypan blue exclusion. Addition of C75 significantly incrreases the 
number of dead cells, with maximal death when PEL are treated with 10 µM 
LY294002 and 10 µg/mL C75. For the comparison between PEL treated with 
only LY294002 vs. LY294002 plus C75: P ≤ 0.05 
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DISCUSSION 
 We report that PEL and other B-NHL display increased glycolytic activity. 
PEL are highly sensitive to Glc withdrawal and the glycolysis inhibitor, 2DG. 
Lactate, a byproduct of glycolysis, is present in high levels in the growth media of 
PEL. These data are in line with clinical observations of elevated serum levels of 
lactate dehydrogenase (LDH) correlating with poor prognosis in patients with 
lymphomas (42). LDH converts pyruvate, the end product of glycolysis, into 
lactate. Our flux measurements confirm upregulated rates of glycolysis in B-NHL 
cells as compared to primary B cells from healthy donors. Additionally, KSHV 
infection of endothelial cells was previously shown to increase glycolysis (43). 
 We found that PEL express high levels of FASN, whereas FASN 
expression or biosynthetic activity in human primary B cells was barely 
detectable. We report that FAS inhibition by C75 reduced the viability of PEL and 
other B-NHL, while primary B cells remain largely unaffected by C75 treatment. 
Moreover, C75 also sensitized PEL cells to the PI3K inhibitor LY294002. This 
might be a case of oncogene addiction where cancer cells are highly sensitive to 
inactivation of a pathway that they depend on (44), while normal cells are not 
sensitive to this inactivation. The PEL proliferate continuously, and when FAS is 
inhibited, the cells end up undergoing apoptosis because there is a lack of lipid-
derived building blocks required to make daughter cells. This provides the 
opportunity to use molecular targeted therapy against B-NHL that preferentially 
kill B-NHL while sparing primary B cells. 
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Notably, despite heightened FAS, PEL cells displayed FAO rates that 
were not significantly different than those of primary B cells. In primary cells, FAS 
and FAO are carefully counter-regulated, since FAS utilizes ATP, whereas FAO 
generates ATP (45). Thus, concurrent FAS and FAO within the same cell, as 
exhibited by PEL, would be an energetically futile occurrence. However, 
coordinate regulation of FAS and FAO appears to be lost in PEL, which have 
highly upregulated rates of FAS, whereas FAO rates remain quite similar to 
primary B cells. Elevated FAS rates in PEL contribute to an abundance of de 
novo synthesized, Glc-derived triglycerides and phospholipids, suggesting that 
newly-generated fatty acids are rapidly incorporated into membrane lipids and 
triglyceride stores to accommodate the dramatic proliferative rates of lymphoma 
cells. Precursors derived from other biochemical pathways such as 
glutaminolysis, can input into FAS.  However, their relevance in the context of B-
NHL remains to be determined. Our data indicate that upregulated FAS is a 
characteristic of B-NHL, and that FASN might be an efficacious therapeutic target 
against B-NHL, while sparing normal, primary B cells. 
  We report that glycolysis and FAS are intertwined in PEL and other B-NHL  
since inhibition of glycolysis affected FAS and vice versa. The fact that inhibition 
of glycolysis causes a reduction in FAS demonstrates that glycolysis fuels the 
synthesis of fatty acids in PEL and B-NHL by providing acetyl-CoA intermediates. 
Conversely, FAS inhibition may result in decreased glycolysis, if the cells sense 
that the glycolytic intermediates required to fuel FAS are unnecessary, due to 
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decreased FASN biosynthetic activity.  Thus, these two metabolic pathways 
appear to be linked in B-NHL. 
Fatty acids are essential for subsequent synthesis of macromolecules and 
cell membranes, both of which are necessary for rapidly dividing cancer cells. 
Interestingly, primary B cells stimulated to proliferate with LPS upregulated 
glycolysis, along with a concurrent expression of FASN; however, in proliferating 
primary B cells, the rate of neither pathway was comparable to the high degree of 
glycolysis and FAS taking place in untreated PEL. These data suggest that 
enhanced FAS and upregulated FASN expression is an advantageous metabolic 
adaptation of PEL and other B-NHL. In concordance with our observations, 
several groups have reported instances of hypertriglyceridemia and 
hyperlipidemia in patients with leukemia and lymphoma (46, 47) and clinical 
remission of disease was shown to coincide with plasma lipid and triglyceride 
levels returning to baseline. PI3K/AKT pathway activation in PEL contributes to 
the increase in both glycolysis and FAS, since treatment of PEL with a non-
cytotoxic dose of the PI3K inhibitor LY294002, reduced the rate of glycolysis as 
well as FASN expression, thus diminishing the rate of FAS. However, in primary 
B cells, LY294002 decreased glycolytic flux, but did not affect the rate of FAS.  
 Collectively, our data suggest that hyperactivated FAS is essential for the 
growth advantage of B-NHL. Further, these data indicate that combining existing 
therapeutics targeting the PI3K/AKT/mTOR pathway with FAS inhibitors may be 
an efficacious therapeutic strategy for non-Hodgkin lymphomas. 
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 CHAPTER 4: THE KSHV VIRAL PROTEIN KINASE ACTIVATES THE 
PI3K/AKT/mTOR SIGNALING PATHWAY   
 
INTRODUCTION 
 Viruses have a relatively small genetic payload, yet engage in complex, 
interweaving relationships with their eukaryotic hosts. Viral proteins hijack host 
cell machinery in order to replicate, disseminate and propagate. Additionally, 
large DNA viruses like KSHV also encode proteins that are functional mimics of 
homologous cellular proteins. The repertoire of KSHV mimics of cellular proteins 
includes cytokines (e.g. vIL-6,) (1) cell cycle control proteins (e.g. vCyclin) (2), 
anti-apoptotic proteins (e.g. vFLIP) (3), and immune-modulatory proteins (e.g K1, 
a B cell receptor homolog) (4). In addition, some viral proteins possess domains 
with enzymatic function homologous to eukaryotic enzymes, such deubiquitinase 
activity of ORF64 (5), and the kinase activity of ORF36, also known as viral 
protein kinase (6). Thus, viral proteins capable of post-translational modifications 
alter the cellular proteome.  
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Protein kinases (PKs) are enzymes that catalyze the transfer of phosphate 
groups from energetic nucleotide triphosphates such as ATP or GTP, onto 
specific residues of substrate proteins. Phosphorylation of the target protein 
generates a conformation change, which alters its properties, such as location, 
enzymatic activity and association with other cellular proteins, resulting in a 
functional change in the associated biological pathway. PKs are subdivided into 
serine/threonine (S/T) or tyrosine (Y) kinases, depending on their substrate 
specificity. The human genome codes for about 500 PKs, and up to 30% of all 
cellular proteins are modified by kinases (7). Kinases regulate most cellular 
pathways and are essential players in transducing signals within the cell. PKs 
phosphorylate these specific residues in their target substrates. These residues 
are flanked by specific, often conserved amino acid sequences called consensus 
sequences; kinases generally phosphorylate groups of substrates sharing 
consensus sequences. Most PKs have conserved catalytic sites: an N-terminus 
glycine-rich stretch proximal to a lysine, which is essential for binding ATP, and a 
catalytic loop consisting of an aspartic acid which imparts catalytic activity to the 
kinase. There are seven classes of protein kinases: AGC, CaM , CK1, CMGC, 
STE, TK and TKL kinases. 
Herpesviruses are large, enveloped viruses with double-stranded DNA 
genomes. The human herpesviruses (HHV) are divided into three families, α, β 
and ɣ. Herpes simplex virus 1 and 2 (HSV1 and HSV2) and Varicella Zoster virus 
(VZV) are α-herpesviruses. Human cytomegalovirus, roseolaviruses (HHV6) and 
HHV7 are examples of β-herpesviruses. Epstein-Barr virus (EBV) and Kaposi’s 
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sarcoma-associated herpesvirus (KSHV) are ɣ-herpesviruses.  KSHV was the 
eighth human herpesvirus identified, and is linked to Kaposi’s sarcoma, primary 
effusion lymphoma and multicentric Castleman’s disease. 
α-herpesviruses encode the Us3 kinase family, which inhibit apoptosis and 
disrupt the nuclear membrane. In addition, both α- and ɣ-herpesviruses encode a 
thymidine kinase critical for viral replication as it phosphorylates nucleosides 
including thymidine. A third type of viral-specific kinase is homologous both in 
genome position and amino acid sequence, among all herpesviruses. This 
kinase is denoted the conserved herpesvirus-encoded protein kinase (CHPK). In 
KSHV, this is encoded by ORF36, and is often called vPK. 
 KSHV primary infection begins when the viral envelope glycoproteins K8.1 
and gB first interact with extracellular heparan sulfate, which brings viral particles 
close to cell surface receptors. Several putative receptors such as the αvβ5, 
α3β1 and αvβ3 integrins facilitate KSHV entry into endothelial cells, however, 
they are not the sole receptors (8). The cysteine: glutamate transport protein xCT 
is involved in facilitating entry into adherent cells, whereas dendritic cell-specific 
intercellular adhesion molecule-grabbing nonintegrin (DC-SIGN) is implicated in 
the case of dendritic cells, macrophages and B cells. Once KSHV has attached 
to cell surface receptors, it is brought into the cell by endocytosis. Within the 
endosome, the lipid-rich viral envelop fuses with the lipid-rich endosome 
membrane, which releases the viral capsid and tegument into the cytosol. Thus, 
viral proteins that comprise the tegument enter the host cytoplasm early during 
infection and contribute to how the viral lifecycle proceeds. Upon infection, KSHV 
	   135 
can either enter the latent phase or the lytic phase of its lifecycle. Latency is 
associated with minimal protein expression, while lytic replication generates 
progeny virions that can infect naïve cells. 
 Life-long latency is a defining characteristic of all herpesviruses, KSHV 
latency is characterized by replication of the viral episome by the cellular 
replication machinery and minimal viral protein expression in order to evade host 
immune detection. Lytic reactivation periodically occurs, initiated by diverse 
stimuli including secondary viral infections (9), pro-inflammatory cytokines (10) 
and stressors such as reactive oxygen species (11).  
Herpesvirus lytic gene expression is temporally classified into three 
distinct classes: immediate early (IE), early (E) and late (L). Lytic replication is 
initiated by a single viral protein called replication and transcription activator 
(RTA/ORF50); RTA is the first transcript detected in lytic cells. RTA binds to 
RTA-responsive elements in viral promoters of IE genes, leading to their 
transcription and consequent expression. Thus, RTA activation is a linchpin for 
lytic replication.  
The RTA-responsive IE proteins are actively transcribed despite the 
presence of the protein synthesis inhibitor cycloheximide. The currently known IE 
proteins, RTA itself, ORF45 and K8 all serve as transactivators of E proteins. As 
described in the introductory chapter, ORF45 activates PI3K/AKT/mTOR 
signaling.   
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E genes are the next class of viral genes transcribed during lytic 
replication. By definition, E genes are sensitive to cycloheximide and are 
expressed independent of viral DNA synthesis. The main function of E gene 
products is to facilitate viral DNA replication. Thymidine kinase, DNA polymerase, 
and ribonucleotide reductase are examples of E genes. Once critical levels of E 
genes build up, viral DNA replication commences in the nucleus, at the two origin 
replication sites (ori-lyt) by the rolling circle mechanism.  
L gene transcription begins once viral replication commences. Most L 
gene products are structural proteins that assemble to form the capsid and the 
envelope, whereas some are incorporated into the tegument. Once 
stoichiometric amounts of various L proteins have accumulated, capsid assembly 
of progeny virions begins in the nucleus. Newly assembled capsids exit the 
nucleus, acquire a protein-rich tegument, and are then cocooned by a 
glycoprotein-studded, lipid-rich envelope. These mature progeny virions exit the 
host cell by lysing, and are free to infect new cells.  
Previous studies indicate that vPK is incorporated into the KSHV virion (6). 
Therefore, upon tegument release, vPK enters the cytoplasm and can 
phosphorylate both viral and cellular proteins relatively early in the viral lifecycle. 
Furthermore, vPK is classified as a late gene, since it is expressed concurrent 
with viral replication. Ectopic expression of vPK in uninfected cells results in 
phosphorylation of an important transcription factor c-Jun N-terminal kinase 
(JNK) and the Mitogen-activated kinases MKK4 and MKK7 (12). Ablating vPK’s 
kinase activity by mutating the kinase catalytic site prevented JNK activation, 
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suggesting that vPK directly phosphorylates JNK. Binding assays revealed that 
vPK, JNK, MKK4 and MKK7 form an intracellular complex. Reactivated PEL cells 
were found to contain phosphorylated JNK, and inhibiting JNK activation reduced 
expression of viral late (but not early) genes. This was the first indication that 
vPK may regulate the KSHV lifecycle by manipulating viral or cellular 
transcription.  
Subsequently, Izumiya and colleagues reported the physical association 
of vPK with K-bZIP, a viral protein which binds the viral origin of replication (Ori-
Lyt) (13). VPK-mediated phosphorylation of K-bzip reduced its ability to repress 
viral transcription. Furthermore, the ORF34-37 gene cluster, in which vPK 
(ORF36) is contained, is activated by hypoxia due to a functional hypoxia-
responsive element in the ORF34 promoter (14). Both pleural effusions and 
Kaposi’s sarcoma are often hypoxic, due to the high cell density and tumor 
volume, which reduce the local oxygen supply.  Hypoxia presents a barrier to 
viral propagation, because it down-regulates protein synthesis in an mTOR-
regulated, 4EBP1-dependent manner (15). Therefore, it is possible to presume 
that a viral protein expressed during sub-optimal conditions like hypoxia, may 
actually serve to alleviate the effects of hypoxia on the host cell. Therefore, we 
decided to investigate whether vPK, already known to post-translationally modify 
a host of cellular proteins (16), may alleviate PI3K/AKT/mTOR inhibition. 
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METHODS 
Cell Culture  
Human embryonic kidney-293 (HEK293) cells were cultured in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/ml Penicillin 
G, 100 µg/ml Streptomycin, and 2 mm L-glutamate. Immortalized rhesus 
macaque skin fibroblasts (i.e., RhF) with puromycin resistance were described 
previously (17). Immortalized human umbilical vein endothelial (huvecs) were 
cultured in endothelial cell growth medium supplemented with 10% heat-
inactivated fetal bovine serum, as previously described (18). All cells were 
cultured at 37°C in 5% CO2. 
Inhibitors 
Rapamycin, LY294002 and Torin were purchased from LC Biosciences, 
Calbiochem and Cayman Chemical, respectively.  
MTS cell proliferation assay 
To observe alterations in growth and proliferation, 1 X 104 HEK293 cells 
were treated with the therapeutic compounds at the indicated doses or with 
appropriate vehicle as a negative control. Cells were followed for 72 hours, and 
cell viability was determined by trypan blue exclusion performed in quadruplicate. 
Actively metabolic cells were quantified every 24 hours using the Cell Titer 96® 
Aqueous One Solution Cell Proliferation Assay (Promega) according to the 
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manufacturer’s instructions. Absorbance was measured using Fluostar OPTIMA 
(BMG Labtech).  
Western blots 
Cells were treated with various compounds as indicated.  After washing 
harvested cells with ice-cold PBS, cell lysates were prepared in a buffer 
containing 150 mm nacl, 50 mm Tris-HCl (ph 8), 0.1% NP40, 50 mm NaF, 30 
mm β-glycerophosphate, 1 mm Na3VO4 and 1x Complete Protease Inhibitor 
cocktail (Roche). Equal amounts of proteins were electrophoresed on either 10 or 
12% SDS-PAGE denaturing gels, followed by transfer onto a Hybond™-ECL 
nitrocellulose membrane (GE Healthcare). Membranes were blocked with 5% fat-
free milk for 1 hour at room temperature, followed by overnight incubation at 4°C 
in the indicated primary antibodies directed against either phosphorylated or total 
protein.  The following primary antibodies against phosphorylated proteins were 
used: AKT (Ser473), AKT (Thr308), mTOR (Ser2448), S6K (Thr421/Ser424), S6 
ribosomal protein (Ser235/236) (Cell Signal). Tubulin (Cell Signal) was used as a 
loading control, and anti-vPK antibody was a kind gift of Dr. Yoshihiro Izumiya 
(UC Davis). After washing, the membrane was incubated with anti-rabbit igg 
conjugated to HRP. The results were visualized with the ECL Plus Western 
Blotting Detection System (GE Healthcare) according to the manufacturer's 
instructions. 
Recombinant protein production and purification 
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Large scale cultures (ten T150 flasks) of Spodoptera fugiperda SF9 cells, 
maintained at 27°C in EX-CELL 420 medium (Invitrogen) were infected with 
baculoviruses encoding FLAG-tagged ORF36 for 48 hours. Expression of ORF36 
was confirmed by immunoblotting. Cells were harvested with FLAG lysis buffer 
(50 mm Tris-hcl [ph 7.5], 500 mm nacl, 1 mm EDTA, 1% Triton X-100) 
supplemented with Complete© protease inhibitor cocktail. Cell lysate was cleared 
by centrifugation and FLAG-tagged ORF36 was immunoprecipitated using anti-
FLAG antibody-conjugated agarose beads (Sigma), as per the manufacturer’s 
instructions. Protein was eluted with 150 µg/ml of 3x FLAG peptide (Sigma) in 
TBS buffer. Purification was confirmed with immunoblotting.  Silver staining of 
SDS-PAGE gels was carried out to determine protein concentration by 
comparison to a BSA standard.  
In vitro kinase assay 
Purified kinases were first adjusted to 100 ng/µl in kinase dilution buffer 
(50 mm Tris-HCl ph 7.5, 0.1 mm EGTA, 1 mg/ml BSA, 0.1% (v/v) 2-
mercaptoethanol). 100 ng kinase was incubated with 2 µg of S6 peptide 
(Carboxy terminus -STSKSESSQK- amino terminus) in kinase reaction buffer (20 
mm HEPES pH 7.5, 5 mM Mncl2, 10 mM 2-mercaptoethanol) supplemented with 
10 µCi [ɣ-32P] ATP (Perkin-Elmer) at 37°C for 30 minutes, after which the entire 
reaction was spotted onto P81 phosphocellulose paper and plunged into 75 mm 
H3PO4 to terminate the reaction. Phosphocellulose papers were washed three 
times and allowed to dry at room temperature after the last wash, and placed in 
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scintillation vials. Counts were assayed using liquid scintillation counting (Perkin-
Elmer). 
Genome quantification and plaque assay 
Genome quantification was performed by qPCR and comparison to known 
standards, as previously described (19); Rhesus monkey Tubulin gene was used 
as an endogenous housekeeping control. Plaque assays were performed by 
infecting confluent primary Rhesus fibroblasts with viral supernatants, as 
previously described (17). 
 
RESULTS 
KSHV vPK phosphorylates cellular proteins that regulate host protein 
synthesis 
Eukaryotic expression vectors were transiently transfected into HEK293 
cells for 48 hours, after which cells were harvested, and prepared lysates were 
subjected to immunoblotting. Probing membranes with phospho-specific 
antibodies indicated that vPK expression increased phosphorylation of S6 
ribosomal protein (S235/236), eukaryotic initiation factor 4B (eIF4B) (S422) and 
4E binding protein (4EBP1) (Th37/46), as shown in Figure 1. In data not shown, 
these increases were found to correlate with the amount of transfected DNA, 
thus attributing enhanced phosphorylation of these cellular targets with levels of 
vPK expression. Tubulin is shown as a loading control. 
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Figure 1: vPK activates proteins downstream of PI3K/AKT/mTOR signaling. 
Immunoblot analysis of vPK-transfected HEK293 cells demonstrates increases in 
phosphorylated S6, eIF4b and 4EBP1 proteins, correlating with vPK expression; 
these increases are absent in vector and mutant vPK K108Q (kinase dead)-
expressing cells.  
vPK expression confers resistance to PI3K/AKT/mTOR inhibitors  
As described above and in methods, cells were transfected with vPK for 
48 hours. Cells were cultured in reduced serum (2%) medium for a further three 
hours, after which cells were treated with 10 nm of either LY294002 (PI3K 
inhibitor), Rapamycin (mTORc1 inhibitor) or Torin1 (mTORc1 and 2 inhibitor), or 
the vehicle control (DMSO) for 30 minutes, and then harvested. Cell lysates were 
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subjected to immunoblot analysis. Analysis of the immunoblots with phospho-
specific antibodies indicated sustained phosphorylation of PI3K/AKT/mTOR 
effector proteins, namely S6, eIF4E and 4EBP1, despite treatment with these 
inhibitors (Figure 2).  
 
 
Figure 2: vPK imparts resistance to PI3K/AKT/mTOR inhibitors. Phosphorylation 
of S6, eIF4e and 4EBP1 is sustained in vPK-expressing HEK293 cells, in spite of 
treatment with LY294002, Rapamycin or Torin. This effect is absent in vector- 
and mutant vPK-expressing cells.  
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Treating cells stably expressing vPK with increasing doses of the mTOR 
inhibitors Torin1 and Rapamycin did not significantly inhibit cell proliferation as 
measured by MTS activity (Figure 3A and 3B, respectively), although this effect 
was lost at higher concentrations of both inhibitors (greater than 10 µM). The 
corresponding vector-expressing cells succumbed at all doses of the inhibitor.   
 
   A      B 
Figure 3: vPK protects cells from mTOR inhibition. HEK293 cells stably 
expressing vPK, mutant vPK or vector were treated with increasing doses of 
Torin1 (Panel A, left) or rapamycin (Panel B, right) for 72 hours, and cell viability 
was analyzed by MTS assay. VPK expression confers resistance to these 
inhibitors, whereas mutant- and vector-expressing cells succumb to these 
treatments.   
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Ɣ-herpesvirus replication ensues in the presence of PI3K/AKT/mTOR 
inhibitors 
To test whether resistance to PI3K/AKT/mTOR inhibitors occurs in the 
context of the KSHV viral lifecycle, we first infected htert-HUVEC with KSHV by 
spinoculation, as described previously (20). Following infection, cells were 
cultured at 37°C for one hour in reduced-serum (2%) medium containing 10 nm 
of Torin1, after which cells were harvested and lysates prepared and subjected to 
immunoblotting as described above. As previously reported, KSHV infection 
leads to phosphorylation of AKT at Ser473 (1) (Figure 4). p70S6K and it’s 
substrate ribosomal S6 protein were also phosphorylated at sites denoting their 
activated status in KSHV-infected cells, as previously described. Surprisingly, 
phosphorylation of both of these targets was maintained despite treatment with 
Torin1, the inhibitor of mTOR which is the upstream kinase responsible for 
regulating both S6K and 4EBP1 phosphorylation; 4EBP1 was also inhibited (by 
phosphorylation) in KSHV-infected cells treated with either vehicle or Torin1, 
(data not shown). Torin1 inhibits both mTOR kinase activity, and therefore can 
countermand mTORc2 feedback activation of AKT by phosphorylation at S473. 
We see a corresponding loss of activated AKT in KSHV-infected, Torin1-treated 
htert HUVEC cells, thus confirming the on-target effect of the compound.  
 
	   146 
   
Figure 4: mTOR targets are activated in KSHV-infected hTERT-HUVEC. 
Phosphorylated S6K, S6 and 4EBP1 levels are sustained in spite of treatment 
with mTOR inhibitor Torin1, in infected cells.  
 
Rhesus Rhadinovirus (RRV), the simian homolog of KSHV, infects and 
replicates to high titers within permissive rhesus fibroblasts, making this a useful 
model system to study the ɣ-herpesvirus lytic lifecycle. At a low multiplicity of 
infection (MOI of 0.1), RRV genome replication occurs in the presence of the 
mTOR inhibitor rapamycin (10 nm) as shown in Figure 5A, and to similar levels 
as vehicle-treated cells. Significantly, infectious virion production is also 
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impervious to rapamycin, as evidenced in equivalent plaque-forming units 
(Pfu/ml) of virus derived from both vehicle- and rapamycin-treated cells (Figure 
5B).  
 
 
 
Figure 5: RRV lytic lifecycle is impervious to rapamycin treatment. RRV genome 
amplification (panel A, top) and infectious virion production (panel B, bottom) 
ensues in the presence of 0.5 um rapamycin, at levels similar to vehicle-treated 
infected RhF. 
 
 
A.	  
B	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vPK exerts kinase activity downstream of PI3K/AKT/mTOR kinases 
To determine the mechanism by which vPK-dependent activation of 
PI3K/AKT/mTOR downstream targets occurs, we tested whether vPK 
phosphotransferase activity extends to these effector proteins. 100 ng of vPK 
purified from SF9 insect cells was incubated with different synthetic peptides, and 
in an in vitro kinase reaction as described above. The unrelated CDK1 substrate 
EF1 α, which served as a negative control. Analysis of the background-
subtracted counts indicated that vPK efficiently and specifically phosphorylates 
S6 peptide (Figure 5), at levels comparable to the upstream regulatory cellular 
p70 S6 Kinase.  
       
Figure 6: KSHV vPK phosphorylates a synthetic S6 peptide in an vitro kinase 
reaction. 
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DISCUSSION 
As an obligate intracellular parasite, KSHV depends on the host for 
replication, propagation and dissemination. To ensure fulfillment of all the 
necessary requirements for successful replication, KSHV encodes a plethora of 
viral proteins, many of which are multi-functional and have diverse effects upon 
the host cell depending upon which compartment they are expressed in. These 
viral proteins alter the cellular signaling milieu by interacting with cellular 
adaptors (e.g. LANA), acting as scaffolds to bring cellular proteins together (e.g. 
ORF45), or by possessing enzymatic function allowing direct modification of host 
proteins (e.g. ORF64). An example of the latter is the viral protein kinase (vPK), 
which phosphorylates serine and threonine residues in specific proteins. 
Preliminary studies demonstrated that vPK activates JNK signaling, thereby 
putatively activating cellular and/or viral transcription programs. Significantly, 
although vPK is expressed late during the viral lifecycle, studies revealed that 
vPK is a tegument protein, therefore it may activate cell signaling during primary 
infection of naïve cells.  
A recent report uncovered a plethora of vPK targets using a 
phosphoproteomics approach (16). Recombinant eukaryotic substrates were 
purified from yeast and spotted onto glass micro-slides, and subsequently 
incubated with purified vPK in an in vitro kinase reaction. An astonishing 178 
cellular proteins were found to be putative vPK targets. Using a systems biology 
approach to analyze these results, vPK (and indeed, all other conserved 
herpesvirus kinases) was found to target proteins involved in the cellular 
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response to DNA damage, and the histone acetyltransferase TIP60, an upstream 
regulator of DNA damage response (DDR) was specifically found to be essential 
for efficient α-, β-, and γ-herpesvirus replication (16). 
The objective of the current study was to determine whether vPK activates 
the cellular PI3K/AKT/mTOR signaling pathway. Using an overexpression 
approach, vPK was found to activate downstream effectors of PI3K/AKT/mTOR 
signaling, specifically the ribosomal S6 protein, the eukaryotic initiation factors 4E 
and 4B as well as the repressor 4E binding protein.  
Phosphorylation of these effectors was sufficient to overcome upstream 
inhibition by compounds such as the PI3K inhibitor LY294002, the mTORc1 
inhibitor rapamycin and the mTOR kinase inhibitor Torin1. Moreover, vPK 
expression in cells treated with these inhibitors conferred a survival advantage 
over an extended period of 72 hours, whereas vector-expressing cells 
succumbed to the growth-inhibitory effects of these compounds.  
Since vPK is a tegument protein, we tested whether resistance to mTOR 
inhibitors occurs early during KSHV infection. Indeed, we found phosphorylation 
of S6, 4EBP1 and eIF4e was sustained in Torin1-treated hTERT-HUVECs 
following infection. Additionally, because vPK is a late lytic protein, it is possible 
that resistance to PI3K/AKT/mTOR inhibitors may also occur late in the lytic 
lifecycle. Therefore, we measured RRV lytic replication 72 hours following 
infection in the presence of PI3K/AKT/mTOR inhibitors. RRV genome 
amplification and progeny virion production was found to be impervious to 
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rapamycin. Two major caveats prevent us from concluding that resistance is 
imparted by vPK expression: the lack of a vPK-deleted recombinant KSHV (or 
RRV) virus, as well as the difficulty in detecting endogenous vPK protein 
following infection by immunoblot, despite the existence of a vPK-specific 
antibody.  
To arrive at a mechanism by which resistance to upstream kinase 
inhibitors was attained, we performed an in vitro kinase assay using recombinant 
vPK and synthetic S6 peptide as the substrate. We found that vPK 
phosphorylates S6 peptide at the same residues phosphorylated by cellular S6K, 
which corresponds with activation of protein translation (7). These data suggest 
that vPK can bypass any inhibitory signaling upstream of S6, and directly activate 
protein translation by phosphorylating S6 ribosomal protein. This is significant 
considering that PI3K/AKT/mTOR-hyperactivation can improperly activate S6, 
and this is a common occurrence in neoplasms. Moreover, KSHV is an 
oncogenic herpesvirus, so determining whether sporadic expression of vPK, a 
lytic protein, contributes to KSHV-associated tumorigenesis is a future goal. 
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Figure 7: Proposed model for vPK’s function in the host cell. By acting 
downstream of PI3K, AKT and mTOR, vPK imparts resistance to 
inhibitors to these kinases by directly phosphorylating their effector 
proteins. 
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CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
 
GENERAL SUMMARY 
 Investigating the interplay between the oncogenic herpesvirus KSHV and 
host cell PI3K/AKT/mTOR signaling is the broad goal of my dissertation research, 
performed under the guidance of Dr. Blossom Damania. Specifically, I studied 
the extent to which KSHV manipulates host cell signaling, metabolism and 
protein synthesis to ensure viral persistence, and the resulting consequences for 
the host. My dissertation research has confirmed the rationale of using 
PI3K/AKT/mTOR-targeted inhibitors for KSHV-associated primary effusion 
lymphoma (PEL). My work has also generated hypotheses and opened up 
diverse research into the nascent field of KSHV-driven metabolic reprogramming. 
Further, the discovery of a novel substrate for the viral protein kinase (vPK) 
poses the question of its functional relevance for the viral lifecycle. Further 
investigation into this biology may uncover fascinating insights into the ability of 
KSHV to usurp and manipulate host cell processes.   
 Chapter One provides a broad background of the KSHV lifecycle, and 
literature reviews describing how four viral proteins alter the cellular 
PI3K/AKT/mTOR signaling pathway, and the implications for oncogenesis. In 
Chapter Two, I confirmed that KSHV-infected primary effusion lymphoma (PEL) 
	   156 
cells are addicted to PI3K/AKT/mTOR signaling, and, using a preclinical mouse 
model of PEL, found that exploiting this dependence is an efficacious therapeutic 
strategy. In Chapter Three, with the help of metabolomics, I discovered 
extensively altered cellular metabolism in PEL, specifically upregulated glycolysis 
and fatty acid synthesis. Using classical biochemical flux analyses, I confirmed 
this metabolic reprogramming in PEL and other B-NHL, was PI3K/AKT-
dependent, and identified metabolic pathways that various B-NHL are reliant 
upon. I further found that this reliance results from abnormal activation of the 
metabolic oncogene FASN, whose inhibition selectively kills B-NHL while sparing 
normal cells; thus, I have discovered a new molecular target for B-NHL 
therapeutics. In Chapter Four, I discovered that the KSHV viral protein kinase 
activates PI3K/AKT/mTOR signaling, and the functional implications of this 
protein’s expression in the context of both the latent and lytic stages of the KSHV 
life cycle.  
 Although all three chapters comprise three distinct projects undertaken 
during my graduate career, at their confluence is a common theme: that viruses, 
as obligate intracellular parasites, manipulate the host cell in diverse ways. 
KSHV encodes several proteins that mimic or hijack the function of eukaryotic 
proteins to acutely alter the cellular signaling milieu and propagate the virus. My 
dissertation places the PI3K/AKT/mTOR pathway at the nexus of viral latency 
and lytic replication. KSHV viral proteins directly and indirectly activate 
PI3K/AKT/mTOR signaling in both lytic and latent stages of the lifecycle, with the 
unintentional consequence of cancer in the host, resulting from pathway 
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hyperactivation. This chapter synthesizes these independent projects and 
proposes future directions, in order to prepare the groundwork for further 
preclinical research towards safe and effective therapeutics for KSHV-associated 
malignancies, and other B-NHL in general.  
KSHV-associated malignancies are characterized by hyperactive signaling. 
 Kaposi’s sarcoma-associated herpesvirus is an oncogenic herpesvirus 
associated with three neoplasms: Kaposi sarcoma, primary effusion lymphoma 
and multicentric Castleman’s disease. Most human cancers arise from complex 
interplay between environmental factors, genetic predisposition and somatic 
mutations, obscuring the single driver of the neoplasm (1). In contrast, virus-
associated cancers present a model system to study carcinogenesis, as unlike 
other human cancers, viral infection primarily drives tumor development, altough 
cellular co-factors including host immunosuppression are also required. Viral 
oncogenic proteins contribute to the development of neoplasms and facilitate 
their progression, by manipulating cellular proteins to deregulate signaling 
pathways, thereby transforming the host cell. 
 KSHV is an enveloped, double-stranded DNA virus with a protein-rich 
tegument. KSHV infection itself is relatively innocuous, however may manifest as 
KSHV Inflammatory cytokine syndrome (KICS) in some instances (2). KSHV 
persists for the lifetime of the host by hiding from the immune system in a latent 
state, with minimal expression of a limited subset of viral proteins and 
microRNAs transcribed from the latency locus. The host replication machinery is 
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responsible for duplicating the viral genome, which exists as an episome tethered 
to host chromosomes via the viral protein LANA. Latency is a beneficial for KSHV, 
since the limited repertoire of expressed viral proteins generate fewer epitopes, 
thereby hiding KSHV from the host’s immune system. Periodic bouts of lytic 
replication generate progeny virions that can infect naïve cells, thus 
disseminating the virus. Lytic replication places the host cell under stressful 
conditions, due to the increased requirements for nutrients, ATP, nucleotide 
precursors, lipids, etc.  
 Hyperactive PI3K/AKT/mTOR signaling is a common attribute of diverse 
human cancers. This pathway plays a critical role in cell proliferation and survival, 
as discussed in Chapter One. Pathway hyperactivation can result from deletion 
of the negative regulator PTEN and somatic mutations in the PI3K catalytic 
subunit. PI3K/AKT/mTOR signaling has pleiotropic effects, because of the wide 
array of effectors activated by PI3K, AKT or mTOR (3). For example, activation of 
S6K, the mTOR target, activates protein translation. Another example is inhibition 
of apoptosis, mediated by AKT-dependent inhibition of the FOXO family of pro-
apoptotic transcription factors. Therefore, the functional output of 
PI3K/AKT/mTOR signaling depends on: 
1. The kinase which is activated 
2. The effectors of that specific kinase.    
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Figure 1: Schematic of various effectors of the PI3K/AKT/mTOR pathway. 
 
 Hyperactivated signaling results in sustained activation of proteins 
involved in protein translation, metabolism, secretion of angiogenic growth 
factors and cytokines, motility and adhesion, etc. Four KSHV-encoded proteins 
activate PI3K/AKT/mTOR signaling: K1, vIL-6, vGPCR and ORF45 (4). Low 
levels of both K1 and vIL-6 are detected in latent cells, with upregulated levels 
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once lytic replication commences (5). On the other hand, ORF 45 and vGPCR 
are expressed only during lytic replication.  
DUAL INHIBITION OF PI3K AND mTOR INHIBITS AUTOCRINE AND 
PARACRINE PROLIFERATIVE LOOPS IN PI3K/AKT/mTOR-ADDICTED 
LYMPHOMAS 
 Stallone et al described the regression of iatrogenic Kaposi’s sarcoma in a 
renal transplant recipient, once the immunosuppressive agent was switched from 
cyclosporine to rapamycin (6). Following this discovery, Dittmer and colleagues 
demonstrated activation of PI3K/AKT/mTOR kinases and their effector proteins in 
primary effusion lymphoma (PEL) (7). They showed that the allosteric mTOR 
inhibitor rapamycin inhibits PEL proliferation and reduces activation of mTOR 
targets such as S6K. When rapamycin was administered to 
immunocompromised mice bearing subcutaneous PEL tumors (xenografts), 
tumor burden was acutely reduced in rapamycin-treated animals, compared to 
those receiving vehicle 
 We hypothesized that single-agent inhibitors incompletely block the 
PI3K/AKT/mTOR pathway in PEL; as such, dual pathway inhibition would 
overcome the inadequacy of single-agent inhibition of PI3K/AKT/mTOR pathway. 
The hypothesis and pursuant studies directly benefited from the availability of a 
new compound, NVP-BEZ235 from Novartis. This drug blocks the kinase 
activities of both PI3K and mTOR.   
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Figure 2: Various compounds inhibit PI3K/AKT/mTOR signaling either at one or 
two nodes, as shown. mTOR is indirectly inhibited by activating AMPK using 
glitazones. AKT is directly inhibited by Miltefosine and Perifosine, NVP-BEZ235 
inhibits the kinase activity of both PI3K and mTOR kinases.  
 Thus, we were able to directly examine the impact of dual inhibition, as 
compared to single-agent inhibitors of either AKT or mTOR. This relatively 
straightforward first project of my graduate training promised immediate 
preclinical impact, should the dual-inhibitor prove a valuable agent for treating 
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PEL. Moreover, these studies would potentially establish the relative contribution 
of each branch of the PI3K/AKT/mTOR pathway in contributing to the 
hyperproliferative cancer phenotype displayed by PEL, permitting greater basic 
understanding of the oncogenic progression in KSHV-associated malignancies.  
 The results of this study, published in Blood (8), showed that inhibiting 
different arms of the PI3K/AKT/mTOR pathway has differing outcomes for PEL 
cell survival, with dual inhibition being a better strategy compared to single 
inhibitors. A combinatorial approach whereby both the protein synthesis and the 
apoptosis-inhibition arms are targeted greatly diminishes PEL proliferation both in 
cell culture and in an animal model. Based on the results of this study, one may 
speculate that combining PI3K/AKT/mTOR inhibitors with compounds targeting 
other upregulated pathways in PEL such as MAPK or NF-κB may further 
augment their efficacy, with the caveat that NF-κB inhibition seems to reactivate 
KSHV from latency (17). However, dual PI3K/AKT/mTOR inhibition may prevent 
lytic replication in this instance in a two-fold manner: firstly, by blocking the 
expression of viral proteins such as vPK (see Chapter Four) that may bestow 
resistance to PI3K/AKT/mTOR inhibitors; and secondly, by inhibiting signaling 
resulting from viral proteins that are currently present in the cell at stable levels. 
 The potency of dual PI3K/AKT/mTOR inhibition extends to non-viral B-
NHL, e.g. Follicular lymphoma, as evident by work of my colleague Prasanna 
Bhende (9). Collectively, these data reinforce the growing consensus in the field 
of cancer biology that monotherapy, while effective in the short-term, is not as 
effective as dual therapy. Monotherapy may fail due to build-up of resistance to 
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the inhibitor, or activation of compensatory signaling (10). Dual inhibitors apply 
pressure at two different nodes, thus preventing compensatory feedback 
activation, leading to a potentially more beneficial therapeutic outcome. A future 
direction of this study would be to determine whether PEL develop resistance to 
dual inhibitors, and if so, the mechanism by which this occurs. If viral proteins are 
implicated in development of resistance, it will reveal new functions of these viral 
proteins.  
DYSREGULATION OF FATTY ACID SYNTHESIS AND GLYCOLYSIS IN NON-
HODGKIN LYMPHOMA 
 The PI3K/AKT/mTOR signaling pathway regulates many aspects of 
cellular metabolism such as the expression of glycolytic genes, translocation of 
glucose transporter, and both synthesis and oxidation of lipids and fatty acids 
(11). Cellular metabolism is the study of how cells obtain nutrients for fueling 
growth and cell division, and maintaining homeostasis, all of which are crucial for 
the survival of KSHV-infected cells. 
 A flurry of recent publications has revitalized interest in cellular 
metabolism, with a particular focus on studying the extent and mechanism of 
metabolic reprogramming of cancer cells. These publications confirm Otto 
Warburg’s seminal observations that tumor cells perform aerobic glycolysis (12). 
The current understanding of tumor metabolism is that increased glycolysis is 
necessary for generating carbon-based precursors for anabolic pathways (13). 
Relatively little was known about metabolic reprogramming in lymphomas, and 
still less about tumors driven by oncogenic viruses. This led us to investigate 
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whether primary effusion lymphoma (PEL), a B cell malignancy characterized by 
latent KSHV, bore any metabolic alterations. We hypothesized that PEL would 
significantly differ in their metabolic program compared to normal, uninfected B 
cells. The goal of the study was to identify the extent of metabolic reprogramming 
in PEL, a representative B-NHL. These data could aid in the identification of 
novel molecular targets for therapy, and biomarkers for early diagnosis.  
 We used a metabolomics approach to profile metabolites in PEL cells. In 
order to uncover differences from normalcy, we compared both intra- and extra-
cellular metabolites of PEL to those of primary B cells isolated from the blood of 
anonymous, healthy donors. The reasons for this comparison were twofold: 
based on the relative distribution of metabolites, we could determine which 
metabolic pathway was dysregulated in PEL, and investigate whether enzymes 
mediating the dysregulation may serve as molecular targets for chemotherapy. 
Secondly, identifying metabolites specifically generated in PEL but not in normal 
cells may serve as biomarkers for early detection of disease.  
 Global metabolite profiles revealed significantly altered metabolism in PEL, 
compared to primary B cells. We found that glycolytic intermediates were over-
represented in PEL, as were intermediates of fatty acid synthesis. While profiling 
global metabolites is strength of a metabolomics approach, it only offers a static 
representation of the metabolome, rather than the rate at which a specific 
biochemical reaction occurs. Therefore, we employed classical biochemical flux 
determination assays, using radiolabeled precursors. To broaden the scope of 
our experiments, we also included cell lines representative of other B-NHL in our 
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experiments. These included Burkitt lymphoma, follicular lymphoma, and two 
EBV-transformed lymphoblastoid cell lines (LCLs) that we generated.  
Biochemical flux analysis revealed that, like most human cancers, all B-
NHL have an exuberant glycolytic flux, compared to primary B cells. PEL in 
particular, are addicted to glucose, and PEL survival correlated with glucose 
concentration of the growth medium. Further, inhibiting glycolysis was toxic to all 
B-NHL. Metabolomics also revealed other extensive biochemical pathway 
alterations in PEL, whose further study will surely be productive and illuminating. 
Fatty acid oxidation (FAO) rates were not significantly different between B-
NHL lines and primary B cells. This was a puzzling finding, given that FAO is 
capable of efficiently generating vast amounts of ATP that can fuel the energy 
demands of rapidly growing cancer cells. Despite approximately equivalent FAO 
rates, PEL were less efficient than primary B cells at fully oxidizing fatty acids; 
this may indicate an underlying defect in FAO, and merits future study. 
Interestingly, we found that FAO intermediates in primary B cells have a profile 
indicating preferential oxidation of amino acids rather than fatty acids; it would be 
interesting to investigate whether this preference bears functional significance. 
When fatty acid biosynthesis was measured, we found that this pathway is 
highly active in PEL. Fatty acid synthesis (FAS) is an energy-demanding process, 
with the additional cost of diverting carbon precursors into synthesis of fatty acids, 
rather than other more physiologically useful biomolecules. All B-NHL had active 
FAS, with intracellular accumulation of hydrophobic lipid droplets visualized by 
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microscopy. Fatty acid synthase (FASN) synthesizes fatty acids and is expressed 
only in the liver. All peripheral cells obtain requisite fatty acids from circulating 
blood, which contains diet-derived fatty acids and lipids. However, some cancer 
subtypes aberrantly express FASN, therefore FASN has been proposed to be a 
metabolic oncogene (14). We discovered that FASN is over-expressed in PEL, 
compared to primary B cells, which express very little FASN. This means that 
metabolic reprogramming in PEL begins at the level of aberrant protein 
expression. It is possible that viral latent proteins may induce FASN expression, 
since FASN is expressed at lower levels (and therefore FAS rates are 
correspondingly lower) in a few of the B-NHL we analyzed.  Our discovery of an 
enzyme whose expression is restricted to malignant cells indicates that FASN 
may be a molecular target for therapies to treat PEL and possibly, other B-NHL 
(15). 
We tested whether PEL are sensitive to FASN inhibitors. C75 is an 
irreversible inhibitor of FASN, and is a known anorexigenic compound, causing 
acute weight loss and inhibiting feeding behaviors in obese mice (16). We found 
that PEL were acutely sensitive to C75, with reduced FAS rates resulting from 
reduced FASN biosynthetic activity. C75 induced apoptosis in PEL, underlining 
the importance of FAS for PEL survival. Other B-NHL lines were also susceptible 
to C75 treatment, although slightly less than PEL. This may be due to 
comparatively lower FASN expression in other B-NHL. 
C75 treatment decreased the expression of FASN protein, indicating that 
the compound not only blocks FASN enzymatic function, but may also regulate 
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FASN expression, by an as-yet undetermined mechanism. Combining C75 
treatment with LY294002, a PI3K inhibitor, decreased the total concentration of 
each compound required to induce apoptosis. These data hint at the possible 
use of FAS inhibitors as sensitizing agents for PI3K/AKT/mTOR pathway-
targeted therapeutics, such as rapamycin and NVP-BEZ235. 
PEL preferentially synthesize abundant amounts of building blocks for 
daughter cells from glucose, compared to primary B cells. Thus, the reason, 
teleological in part, is that PEL upregulate glycolysis in order to generate FAS 
precursors, which in turn, are incorporated into cell membranes of daughter cells. 
It is possible that a KSHV viral latent protein imparts this phenotype, since it 
would guarantee propagation of the viral episome into new cells. Therefore, 
investigating the mechanism by which FAS is activated by KSHV bears further 
investigation.   
In addition to observing upregulated glycolysis and FAS in PEL, we   
discovered an inextricable link between these two biochemical pathways. We 
found that inhibiting glycolysis abated FAS rates, suggesting that glycolysis 
intermediates are essential for feeding FAS. Conversely, FAS inhibition 
diminished glycolytic flux, possibly because reduction in FASN biosynthetic 
activity may itself reduce the demand for glycolysis-derived intermediates.  
Collectively, these data revealed extensive metabolic reprogramming in 
KSHV-infected PEL cells, compared to uninfected, normal primary B cells.  We 
first discovered which metabolic pathways are altered in PEL, compared to 
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primary B cells. We validated the metabolomics analyses with biochemical flux 
measurements, and discovered that upregulated FAS is driven by abnormal 
expression of FASN. Based on the sensitivity of PEL to FASN inhibitors, and 
their ability to sensitize PEL to other chemotherapeutic compounds, we propose 
FASN to be a target for molecular therapeutics for PEL, and moreover, for other 
B-NHL. These findings were reported in Proceedings of the National Academy of 
Science (15). 
 
Figure 3: Overview of metabolic reprogramming in cancer cells 
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KSHV VIRAL PROTEIN KINASE ACTIVATES PI3K/AKT/mTOR TARGETS 
Chapters Two and Three of my dissertation investigated the 
consequences of PI3K/AKT/mTOR activation in the latently infected host cell. 
Chapter Four of this dissertation uncovers how a viral protein, the KSHV viral 
protein kinase (vPK) activates PI3K/AKT/mTOR signaling. We found that vPK 
activates cellular factors involved in protein synthesis, such as the ribosomal 
protein S6. Using an in vitro approach, we found that S6 is a specific target of 
vPK’s phosphotransferase activity. Our most immediate course of action is to 
identify other cellular substrates of vPK and their relative contributions to cellular 
transformation. Whether vPK expression directly alters protein synthesis, and 
whether viral or cellular proteins are preferentially synthesized remains to be 
investigated, and is a future direction of this study. 
Further, we found that vPK imparts resistance to PI3K/AKT/mTOR-
targeted compounds such as LY294002, rapamycin and Torin1. Because S6 is 
activated during primary KSHV infection, even in the presence of the mTOR 
inhibitor Torin1, it is possible that a tegument-containing viral protein released 
during primary infection imparts this resistance. Moreover, genome replication 
and infectious virion production of RRV, a KSHV homolog, ensues despite the 
presence of PI3K/AKT/mTOR inhibitors. This suggests that γ-herpesvirus 
replication is relatively insensitive to PI3K/AKT/mTOR inhibitors. vPK is 
expressed during de novo and lytic replication, therefore it is tempting to 
speculate that vPK may confer resistance to these inhibitors. It may also explain 
why some instances of KS are refractory to rapamycin treatment. Therefore, it is 
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imperative to further investigate how vPK counteracts pathway inhibitors, to 
preempt adverse events in patients receiving molecular targeted therapies for KS 
or PEL. Further, if vPK is indeed directly responsible for imparting resistance, it 
may be important to find a way to inhibit vPK’s kinase activity. A manuscript 
describing these data is currently in preparation. 
 Collectively, our data suggest that while latent KSHV infection is 
susceptible to PI3K and mTOR inhibitors, lytic replication may be impervious to 
them, due to vPK's ability to activate components downstream of mTOR. 
 
 
Figure 4: Proposed model of how vPK activates downstream effectors of 
PI3K/AKT/mTOR signaling, thus granting resistance to pathway inhibitors 
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